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ABSTRACT
Neuroinflammation can lead to neuronal dysfunction and degeneration as found in
many neurological diseases. Our lab has demonstrated that acetate supplementation is
anti-inflammatory and neuroprotective in rat models of neuroinflammation and Lyme
neuroborreliosis. Acetate supplementation in rats through oral administration of glyceryl
triacetate (GTA) increases plasma acetate and brain acetyl-CoA levels. Acetyl-CoA is a
ubiquitous substrate for several biochemical pathways including carbohydrate, protein,
and lipid metabolism and labeled-acetate is incorporated into the purine and lipid pools.
However, the effect(s) that acetate supplementation has on brain purine and lipid content
have not been quantified. To determine the effects that GTA has on brain energy levels,
we measured nucleotide, phosphagen, and glycogen levels, using high performance liquid
chromatography (HPLC) and a fluorometric assay. Further, we used gas chromatography
to quantify brain cardiolipin content and electron microscopy to quantify neuronal
mitochondria in order to test the effects of GTA on mitochondrial biogenesis. With
single-dose acetate supplementation, we observed increase in brain phosphocreatine
(PCr) and reduction in AMP levels at 4 h. No changes in other brain nucleotides and
glycogen were observed which is consistent with the normal state of rats used in this
study. Long-term acetate supplementation did not alter brain glycogen levels,
mitochondrial number in CA3 neurons or whole brain cardiolipin mass. Based on these
results, we measured the effect of long-term GTA in normal and LPS-induced
xiii

neuroinflammation rats on brain nucleotide, and phosphagen levels. Unlike single-dose
GTA, no significant changes were found in PCr and nucleotide levels.
Nonetheless, single-dose acetate supplementation reduced AMP levels and its
breakdown product, adenosine, is a potent neuromodulator with anti-inflammatory
properties. Therefore, we postulated that long-term acetate supplementation may reduce
neuroinflammation by increasing adenosine formation as a result of altered purinergic
metabolism. To begin to test this hypothesis, we quantified the ability of acetate to alter
brain levels and activity of ecto-5’-nucleotidase (CD73), and the levels of adenosine
kinase (AK) and adenosine A2A receptors using Western blot analysis and HPLC-based
analysis of nucleotide hydrolysis. We also examined how protein levels and activity
differed using both prophylactic and interventional treatment strategies. Prophylactic
acetate supplementation prevented the LPS-induced reduction of brain CD73, increased
CD73 activity, and prevented the LPS-induced increase in AK and A2A levels.
Interventional GTA treatment also increased CD73 and A2AR levels compared to nontreated controls. To better understand the cell types involved in acetate-induced
modulation of adenosine metabolizing enzymes and receptors, we quantified ecto-apyrase
(CD39), CD73, AK, and adenosine deaminase (ADA) enzymes, and adenosine A1 and
A2A receptor levels using Western blot analysis in BV2 microglia and primary astrocytes.
In BV2 microglia, we found that LPS-induced increase in CD73, AK and A2A receptor
levels were prevented by acetate while CD39, ADA, and A1 levels were reduced below
control levels with acetate in presence of LPS. Astrocytes, on the other hand, showed
that CD73 and AK levels were increased with acetate treatment in presence of LPS
xiv

however CD39, ADA, and A2A levels were not altered by acetate plus LPS. Furthermore,
to determine the effect that altered purinergic enzyme levels have on adenosine formation
we measured extracellular adenosine levels in both BV2 microglia and astrocyte cultures
using HPLC after acetate and/or LPS stimulation. However, we did not find any changes
in extracellular levels of adenosine in microglia as well as astrocytes. The lack of
elevation in extracellular adenosine levels may be due to rapid adenosine turnover or
disrupted paracrine signaling in isolated microglia and astrocyte cultures. However,
overall these data support the hypothesis that acetate supplementation can modulate
adenosine metabolism and reduce A2A receptor levels that may contribute to its antiinflammatory properties.
Lastly, we investigated the effect of acetate in the presence and absence of LPS
on fatty acid, phospholipid, and cholesterol content of BV2 microglia in order to
demonstrate whether acetate-induced acetyl-CoA can stimulate lipid synthesis. Using
gas chromatography we found that 1, 5, and 10 mM of acetate in presence of LPS at 2 h
increased the fatty acid content of BV2 cells. However, this increase did not result in
altered phospholipid levels as measured by the phosphorus content of individual
phospholipid classes. A colorimetric assay for cholesterol showed a modest increase in
cholesterol levels with 5 mM acetate. Overall these data suggest that acetate
supplementation stimulates purine and lipid metabolism in brain and glial cultures which
may contribute to its anti-inflammatory properties and potentially stimulate lipid
deposition.
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CHAPTER I
INTRODUCTION
Acetate Supplementation
Acetate supplementation attenuates markers of inflammation in rat models of
neuroinflammation (Reisenauer et al. 2011) and Lyme neuroborreliosis (Brissette et al.
2012), improves the tremor phenotype in a Canavan disease model (Arun et al. 2010b),
offers metabolic support in a brain trauma model (Arun et al. 2010a), and possesses
growth arresting properties in gliomas (Tsen et al. 2013). Acetate supplementation in
animals is induced by oral glyceryl triacetate (GTA) administration which increases rat
plasma acetate and brain acetyl-CoA levels (Reisenauer et al. 2011). Acetyl-CoA, the
metabolically active form of acetate, is a substrate used for various biochemical pathways
including carbohydrate, lipid, and protein metabolism. Hence, gaining a better
understanding about the role of GTA in altering acetyl-CoA pathways can provide
mechanistic insights into the protective effects of acetate supplementation.
With regard to protein metabolism, GTA increases brain histone acetylation
(Soliman & Rosenberger 2011) and reverses the bacterial lipopolysaccharide (LPS)induced hypoacetylation of histone 3 at lysine 9 (H3K9) (Soliman et al. 2012b). Further,
acetate-induced changes in histone acetylation are associated with altered cytokine
expression and reduced inflammatory signaling in glial cultures (Soliman et al. 2013a,
Soliman et al. 2012a). Nonetheless, acetate-induced acetyl-CoA levels through the
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tricarboxylic acid (TCA) cycle and lipid synthesis pathways may contribute to the
beneficial properties of acetate supplementation. Although, radio-labeled acetate gets
incorporated into the TCA cycle (Wyss et al. 2011), the fatty acid synthesis (Howard et
al. 1974) and the cholesterol synthesis pathways (Hellman et al. 1954), the direct effect
that a significant increase in circulating levels of acetate has on brain purine and lipid
metabolism remains unknown.

Disruption of brain energy metabolism and available energy sources
The central nervous system (CNS) depends on mitochondrial energy production
to maintain normal physiological functions like cellular homeostasis and compartment
integrity, intracellular trafficking, formation and uptake of neurotransmitters,
neurotransmission and energy-dependent anabolic reactions (Ames 2000, Morais & De
Strooper 2010). Disruption of mitochondrial function leads to partial plasma membrane
depolarization, activation of NMDA receptors, excitotoxicity, and neuronal death
(Novelli et al. 1988). Glucose and energy metabolism are reduced with increases in
extracellular glutamate content and receptor numbers in the aging brain (Hoyer 1990),
making it more vulnerable to anoxic damage (Roberts & Chih 1995). As early as 1 min
following ischemia, brain ATP and phosphocreatine (PCr) levels fall (Lowry et al. 1964),
and reduced PCr levels are observed in Alzheimer’s disease patients presenting with mild
dementia (Pettegrew et al. 1994). Neurons use PCr to store energy as a reserve which
when required is readily converted to ATP (Meyer et al. 1984). Increasing neuronal PCr
stores protects neurons from hypoxic damage, glutamate toxicity, amyloid β-induced
toxicity (Balestrino et al. 2002, Balestrino et al. 1999, Brewer & Wallimann 2000) and is
2

neuroprotective in animal models of Huntington’s disease (Matthews et al. 1998),
Parkinson’s disease (Matthews et al. 1999), and amyotrophic lateral sclerosis (Klivenyi et
al. 1999). Moreover, direct application of ATP and PCr not only increase α-processing
of amyloid-β precursor protein (APP) in SH-SY5Y cells, but also improve inefficient
APP α-processing in aged human fibroblasts (Sawmiller et al. 2012).
In brain, acetate is preferentially utilized by astrocytes (Waniewski & Martin
1998) and is considered as a glial-specific substrate since labeled-acetate is mainly
incorporated into the synthetic astrocytic-glutamine pool (Minchin & Beart 1975).
During increased metabolic demand neurons depend on astrocytes for rapid removal of
potassium ions and neurotransmitters from the extracellular space to maintain neuronal
activity (Brown 2004). This results in an overall increase in energy demand by both
neurons and astrocytes where astrocytic glycogenolysis may play an important role.
Astrocytic glycogen can serve as an important energy reserve to support neuronal energy
metabolism by sparing extracellular glucose for neuronal utilization (Dinuzzo et al.
2012). However, the influence that utilization of acetate through the TCA cycle has on
normal brain energetics has not been demonstrated.

Ketogenic diet and brain energy metabolism
A close metabolic correlate to acetate supplementation with regard to brain
bioenergetics is the ketogenic diet which increases cellular acetyl-CoA levels (Yudkoff et
al. 2005). The ketogenic diet is a high-fat low-carbohydrate diet used to treat refractory
cases of epilepsy and is considered neuroprotective (Bough et al. 2006). While the
mechanisms underlying the therapeutic effect of the diet remain unknown, a variety of
3

studies suggest mitochondrial bioenergetics to be the key in this regard (Maalouf et al.
2009). Ingestion of the diet produces ketone bodies that cross the blood brain barrier and
are metabolized to acetyl-CoA, which increases mitochondrial biogenesis in hippocampal
neurons and improves brain ATP production (Bough et al. 2006, Nylen et al. 2009).
Mitochondrial biogenesis is a process that stimulates the synthesis of mitochondria,
import of nuclear-encoded proteins, and fusion of organelles to form a network that
increases metabolic function (Nisoli & Carruba 2006). Cardiolipin, a phospholipid class,
mainly located in the inner mitochondrial membrane (Daum 1985) is involved in the
regulation of mitochondrial bioenergetics (Hoch 1992), is important for the activity of
mitochondrial proteins, and can be used as a marker for quantifying mitochondrial mass
(Houtkooper & Vaz 2008, Schlame 2007). Since both acetate supplementation and the
ketogenic diet increase tissue acetyl-CoA levels it is important to study the effects of
GTA on mitochondrial biogenesis.

Neuroinflammation: link to energy metabolism
Neuroinflammation is a common feature shared by many neurodegenerative
diseases including Alzheimer, Parkinson, Huntington, amyotrophic lateral sclerosis, and
multiple sclerosis (Forman et al. 2004). Inflammation is a self-defense mechanism that
involves a complex cascade of biological responses directed towards a noxious tissue
insult or damage in order to promote clearance of tissue debris and repair. CNSinflammation is characterized by activation of neuroglia and associated changes in gene
expression leading to production and release of pro-inflammatory mediators such as
cytokines, prostaglandins, nucleotides, glutamate, nitric oxide, reactive oxygen species
4

(ROS), and proteases (Hanisch 2002). Microglia, the innate immune cells of the CNS,
upon activation release pro-inflammatory mediators and constitute the acute
inflammatory response. This is accompanied by the release of anti-inflammatory
cytokines, lipoxins, resolvins and neuroprotectins (Block et al. 2007, Olson & Miller
2004) which help in resolving inflammation. On the other hand astrocytes, the major cell
type in the brain, play a key role in maintaining CNS homeostasis and mediating
neuroinflammation (Farina et al. 2007). However, prolonged and uncontrolled
neuroinflammatory response to a persistent stimulus or due to disrupted regulation of
inflammatory mediators is thought to be responsible for the progressive nature of various
neurodegenerative diseases (Gao & Hong 2008).
Progressive loss of cellular energy and mitochondrial dysfunction are reported in
several neurological disorders and aging (Beal 1995, Di Filippo et al. 2010). Although a
direct link between CNS inflammation and energy levels has not been established,
mitochondrial dysfunction is a common feature associated with both neuroinflammation
and neurodegeneration. Mitochondrial dysfunction and neuroinflammation are thought to
synergistically trigger a vicious cycle of deleterious effects eventually leading to neuronal
death (Di Filippo et al. 2010). Interestingly, pharmacological inhibition of mitochondrial
components is widely used to induce neuroinflammation and neurodegeneration in
experimental models (Di Filippo et al. 2006). Therefore, increasing cellular energy has
the potential to improve resistance against metabolic insults and slow the progression of
neuroinflammation in neurodegenerative conditions. In this regard, acetate
supplementation prevents ATP loss in a traumatic brain injury model (Arun et al. 2010a)
5

however to date it has not been demonstrated whether neuroinflammation or acetate
supplementation can directly alter brain energy levels.

Rat model of neuroinflammation
A reproducible model of neuroinflammation is generated in rats by infusing a
Gram-negative bacilli endotoxin, LPS directly into the 4th ventricle of the brain (HaussWegrzyniak et al. 1998a, Hauss-Wegrzyniak et al. 1998b). In brain, LPS binds to the
TLR4/CD14/MD-2 receptor complex (Fujihara et al. 2003) that activates neuroglia,
reduces cholinergic immuno-reactivity (Reisenauer et al. 2011), and increases the
expression of the pro-inflammatory cytokine interleukin (IL)-1β (Soliman et al. 2012b).
Increased brain arachidonic acid turnover with increased activity of arachidonic acidselective secretory and cytosolic phospholipase A2 and levels of prostaglandins are
observed in this model (Hauss-Wegrzyniak et al. 1998a, Hauss-Wegrzyniak et al. 1998b,
Hauss-Wegrzyniak et al. 2000, Lee et al. 2004, Rosenberger et al. 2004).

Purinergic signaling and neuroinflammation
Purines comprise of adenine and guanine nucleobases that are the basic units of
nucleosides and nucleotides. Of these the adenine nucleoside (adenosine) and
nucleotides (ATP, ADP, and AMP) are most widely studied. Adenine nucleotides are the
basic energy storage units of the cell, which upon breakdown result in adenosine
formation and help maintain cellular energy balance (Shepel et al. 2005). The production
of adenosine increases with increased energy consumption and is inversely correlated to
the energy charge ratio [(ATP+0.5*ADP)/ (ATP+ADP+AMP)] (Shepel et al. 2005), the
6

metabolically available energy to a cell at any given time (Atkinson 1968). Due to the
inhibitory action on the high energy utilizing processes, adenosine is described as a
“retaliatory metabolite” that reduces cellular metabolic demand and restores energy
levels. Both adenosine and ATP are ubiquitously found in the extracellular space of most
organs and tissues in our body and serve as important signaling molecules (Dunwiddie &
Masino 2001). In the central nervous system, adenosine generally acts as an inhibitory
modulator and plays diverse roles in regulating sleep, arousal, neuronal excitability, and
cerebral blood flow (Dunwiddie & Masino 2001). ATP, on the other hand, is released by
injured neurons or activated astrocytes and promotes microglial chemotaxis and
phagocytosis. The pro-inflammatory effect of ATP is suppressed by its degradation to
adenosine, which modulates the inflammatory response by promoting regeneration and
repair. Therefore, adenosine serves as a link between cellular metabolism and
inflammatory signaling (Fredholm et al. 2001, Klotz 2000).
Adenosine acts as a potent modulator of brain activity by binding to G-protein
coupled purinergic P1 or adenosine receptors (A1, A2A, A2B, and A3) (Masino et al.
2009). Physiological effects of adenosine are primarily mediated by A1 and A2A
adenosine receptors and are largely considered to be neuroprotective (Boison et al. 2010).
Adenosine inhibits neuronal excitability by reducing A1 receptor mediated excitatory
neurotransmitter release while A2A receptors facilitate inhibitory neurotransmitter release
(Cunha 2005). Hence, adenosine is widely studied for its anticonvulsant and
neuroprotective properties (Boison 2005).
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Formation of adenosine can occur both inside as well as outside the cell and
distinct cell-specific mechanisms for extracellular elevation of adenosine levels exist
(Parkinson et al. 2005). Intracellular ATP levels are tightly controlled however under
conditions of hypoxia, ischemia, inflammation, nerve stimulation or stress, astrocytes
release ATP into the extracellular space. Extracellular ATP is sequentially
dephosphorylated to adenosine by a cascade of membrane-bound nucleotidases (Figure
1). The enzymes responsible for extracellular conversion of ATP to adenosine are CD39
(ecto-apyrase, converts ATP and ADP into AMP) and CD73 (ecto-5’-nucleotidase,
converts AMP to adenosine). Alternatively, neurons release intracellular adenosine
formed from the breakdown of adenine nucleotides or cleavage of Sadenosylhomocystein via the nucleoside transporters (Parkinson et al. 2005).
Extracellular adenosine levels elevated by either pathway result in activation of
purinergic P1 receptors. Purinergic signaling by adenosine is terminated by cellular uptake via nucleoside transporters followed by conversion to AMP by AK (adenosine
kinase) or catabolism to inosine by intracellular or extracellular membrane-bond ADA
(adenosine deaminase). However, due to rapid uptake and metabolism, the metabolic
half-life of adenosine is very short (Noji et al. 2004). Thus, therapeutic agents that can
elevate extracellular adenosine levels for prolonged time intervals can be valuable
neuroprotective candidates.
In brain, the innate immune response is initiated by microglia and amplified by
astrocytes, which through glial communication act to propagate the neuroinflammatory
response. It is well known that purinergic signaling is ubiquitous to the brain yet is
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immerging as a key regulatory mechanism that can disrupt neuroglial communication and
reduce neuroinflammation (Di Virgilio et al. 2009b). Both microglia and astrocytes
possess purinergic P1 and P2 receptors and express enzymes that alter extracellular ATP
and adenosine levels which modulate purinergic and inflammatory signaling (Di Virgilio
et al. 2009b). Because adenosine can influence neuronal activity and attenuate
neuroinflammation, being able to modulate adenosine levels or the receptors involved in
purinergic signaling has a broad therapeutic potential (Fredholm et al. 2005a).

Figure 1: Adenosine metabolism across cell membrane (Parkinson et al. 2005).
ATP is released into the extracellular space by activated astrocytes or injured neurons.
Extracellular ATP can directly stimulate purinergic P2X or P2Y receptors, the actions of
which are terminated by its sequential breakdown into adenosine through membranebound nucleotidases. The enzyme CD39 converts ATP and ADP into AMP which is
further broken down into adenosine by CD73. Adenosine stimulates purinergic P1 or
adenosine receptors, followed by uptake via bidirectional equilibrative nucleoside
transporters and subsequent conversion to AMP by the AK enzyme. Alternatively,
adenosine can undergo irreversible breakdown into inosine by enzyme ADA.
Abbreviations: ATP: adenosine triphosphate; ADP: adenosine diphosphate; AMP:
adenosine monophosphate; ADO: adenosine; INO: inosine; CD39: ecto-apyrase; CD73:
ecto-5’-nucleotidase; ADA: adenosine deaminase; AK: adenosine kinase; and ENT:
equilibrative nucleoside transporter.
9

Lipid synthesis and metabolism
Lipids are hydrophobic biomolecules that are insoluble in water but soluble in
organic solvents. This property of lipids is the basis for their role as structural
components of cell membranes. Besides this, their biological functions include energy
storage, lipid-mediated signal transduction, and post-translational lipid-modification of
proteins. The main lipid classes relevant to the study of lipids in brain include
phospholipids, sphingolipids, cholesterol, and fatty acids that form the main components
of biomembranes and are important intermediates in lipid signaling.
De novo synthesis of fatty acids occurs in the cytoplasm from the two carbon
precursor acetyl-CoA by the activity of three major enzymes: acetyl-CoA carboxylase
(ACC, rate limiting), fatty acid synthase (FAS), and the Δ-desaturases. Alternatively,
some fatty acids are produced as a result of β-oxidation in the mitochondria or directly
released from the esterified-phospholipid pool by phospholipase A1 and A2 enzymes.
Thus, the total fatty acid content of a cell at any given time is a total of the esterified and
the non-esterified fatty acid pools. Fatty acids either obtained through diet or de novo
synthesis are incorporated into membrane phospholipids, and the esterifiedpolyunsaturated fatty acids serve as a reserve pool for eicosanoid signaling. Although,
several studies have studied the incorporation of labeled-acetate into the fatty acid and
cholesterol pools (Hellman et al. 1954, Howard et al. 1974), it has not been clearly
demonstrated whether large doses of acetate can stimulate fatty acid synthesis.
Stimulating lipid synthesis is crucial for the treatment of diseases involving
myelin degradation or insufficient myelin synthesis, as in multiple sclerosis and Canavan
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disease, respectively. In this regard, it has been shown that white matter acetate levels
are reduced in human brain from multiple sclerosis patient (Li et al. 2013). On the other
hand, acetate supplementation increases myelin galactocerebrocide levels in a rat model
of Canavan disease (Arun et al. 2010b). Further, aging decreases the poly-unsaturated
fatty acid content and increases the mono-unsaturated fatty acid content of ethanolamine
and serineglycerophospholipids (Giusto et al. 2002). Dietary n-3 polyunsaturated fatty
acids like docosahexaenoate (DHA) and eicosapentaenoate (EPA) reduce inflammation
(Ji et al. 2012) and are thought to do so by replacing arachidonate (ARA) at the sn-2
position of the membrane phospholipids. Thus, it is important to study the effects of
acetate supplementation on brain fatty acid synthesis and lipid deposition in
demyelinating disease models.

Overall hypothesis, approach, and outcomes
The primary focus of this dissertation was to better understand acetate
supplementation-induced acetyl-CoA pathways involving purine and lipid metabolism,
and their contribution towards the anti-inflammatory effects of glyceryl triacetate. In this
regard, the TCA cycle is responsible for energy generation and is linked to purine
metabolism. Purines and their nucleotides are important signaling molecules that mediate
inflammation. Thus we postulated that acetate supplementation reduces inflammation by
modulating purine metabolism. To begin to test this hypothesis, we measured the effect
that short-term acetate supplementation has on brain purine levels using HPLC and found
that single-dose GTA (6g/kg body weight) increases phosphocreatine and reduces AMP
levels in normal rat brains (Bhatt et al. 2013). In parallel experiments, the effect of long11

term acetate supplementation on brain glycogen levels and mitochondrial biogenesis was
measured using fluorometric assay, electron microscopy, and cardiolipin analysis. The
28 day GTA treatment in normal rats does not alter brain glycogen levels or
mitochondrial mass (Bhatt et al. 2013). This study suggested that acetate-induced acetylCoA metabolism stimulates energy production and possibly alters purine metabolism.
Further, long-term acetate supplementation did not alter brain purine levels in normal rats
or rats subjected to neuroinflammation. Since adenosine, a purine nucleoside, is a potent
modulator of the inflammatory response in the brain (Boison et al. 2010, Masino et al.
2009), we sought to measure the activity and levels of enzymes involved in adenosine
metabolism and adenosine receptor levels in a rat model of neuroinflammation. Using
Western blot analysis and HPLC based nucleotide assay, we found that both 14 and 28
day prophylactic acetate supplementation were able to increase CD73 levels and activity
indicative of greater adenosine production. Further, the 28 day prophylactic treatment
reversed LPS-induced increase in AK levels suggesting a reduction in adenosine
degradation compared to the LPS group. The LPS group showed an increase in A2A
receptor levels which were reversed with the 28 day prophylactic treatment. On the other
hand, the interventional acetate supplementation strategy elevated CD73 levels but did
not alter CD73 activity or A2A receptor levels (Smith et al. 2013).
Since multiple cell types are involved in purinergic signaling and the
neuroinflammatory response, we designed in vitro experiments using isolated BV2
microglia and primary astrocyte cultures to determine the contribution of different cell
types towards alteration of adenosine metabolism. Using Western blot analysis, in BV2
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microglia we found that LPS-induced increase in AK and A2A receptor levels were
similar to that found in vivo however increase in CD73 levels was in contrast to the in
vivo decrease, all of which were prevented by acetate. The discrepancy between the in
vivo and in vitro findings may be due to the differential expression of enzymes and
receptors by different brain cell types and their relative contribution to the whole brain
analysis. In addition to these, we also measured CD39 and ADA enzyme and A1 receptor
levels where were only ADA levels were increased by LPS but both CD39 and ADA
levels were reduced to below control levels by acetate in presence of LPS. Astrocytes, on
the other hand, showed that acetate treatment in presence of LPS increased CD73 levels
like in vivo and AK levels unlike our in vivo results. Further, the A2A levels unlike in
vivo results remained unaltered with both LPS and acetate treatment. Additionally, we
also measured CD39, ADA and A1 receptor levels and found that LPS –induced increase
in CD39 levels was not altered by acetate. Moreover, the ADA levels remained unaltered
by both LPS and acetate plus LPS while A1 receptors were below the level of detection.
Acetate-induced increase in astrocytic AK levels may be a compensatory mechanism to
replenish cellular nucleotide levels released from astrocytes and metabolized by CD39
and CD73.
Therefore, we took an alternatively approach to determine the effect of acetate in
the presence and absence of LPS on extracellular adenosine levels in isolated BV2
microglia and astrocyte cultures using HPLC with fluorescence detection. We did not
find any changes in extracellular levels of adenosine in microglia and astrocyte cultures.
The lack of elevation in extracellular adenosine levels may be due to rapid adenosine
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turnover (Noji et al. 2004). Nonetheless, it is possible that purinergic signaling is
dependent upon paracrine communication between different cell types including
microglia, astrocyte, and neurons, and that may have affected the extracellular adenosine
measurements. Therefore, diverse co-culture paradigms including mixed glial cultures
co-cultured in presence and absence of neurons, or organotypic slice cultures may be a
more suitable way to better characterize the effects of acetate on purinergic signaling.
Further, pretreatment of cultures with adenosine uptake and degradation inhibitors can
greatly enhance the chances of detecting changes in extracellular adenosine levels.
Lastly, we investigated the effect of acetate in the presence and absence of LPS
on fatty acid, phospholipid, and cholesterol content of BV2 microglia in order to
demonstrate whether acetate-induced acetyl-CoA can stimulate lipid synthesis. Cellular
esterified and non-esterified fatty acids were converted into their methyl esters and
analyzed using gas chromatography. Total phosphorus content of individual
phospholipid classes was measured using a phosphorus assay and cholesterol levels were
measured using a colorimetric assay. In this proof-of-principle experiment, we found that
acetate showed marked increases in BV2 cell fatty acid content, modest increase in
cholesterol content without altering phospholipid levels (Bhatt & Rosenberger 2013).
These data support the hypothesis that acetate can stimulate fatty acid synthesis in these
cultures but future studies are required to determine if the changes in fatty acid content
are in fact due to an increase in de novo synthesis or reduction in β-oxidation.
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CHAPTER II
METHODS
Reagents
Standards: Nucleotide standards [adenosine, ATP, ADP, AMP, α, β-methylene
adenosine diphosphate (AMPCP), NAD, GTP], and phosphagen standards
[phosphocreatine (PCr) and creatine (Cr)] were purchased from Sigma–Aldrich (St.
Louis, MO).
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C-labeled ATP, ADP, and AMP were obtained from American

Radiolabeled Chemicals, Inc. (St. Louis, MO). Creatinine standard and bovine serum
albumin protein standard (fraction V, fatty acid free) were from MP Biomedicals, LLC
(Solon, OH). The standard 1, N6-ethenoadenosine was from Axxora, LLC (San Diego,
CA). Fatty acid methyl ester standards, phospholipid standards, and cholesterol were
from NuCheckPrep, (Elysian, MN). Western blotting markers, Prestained SDS-PAGE
Standards (#161-0318) and Precision Plus Protein™ WesternC™ Standards (#161-0376)
were purchased from Bio-Rad Laboratories (Hercules, CA).
Chemicals: Sodium acetate (99%), trichloroﬂuromethane (Freon),
chloroacetaldehyde (50%), trioctylamine, glucose, hexokinase, myokinase, glyceryl
triacetate (GTA, 99%), trioctylamine, bacterial lipopolysaccharide (LPS, Escherichia
Coli 055:B5), 6-(p-Toluidino)-2-naphthalenesulfonic acid sodium salt (TNS), ferric
chloride heptahydrate, and gelatin were purchased from Sigma–Aldrich (St. Louis, MO).
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The ion-pair reagent tetrabutylammonium phosphate (TBAP) was purchased from
Mallinckrodt Baker, Inc. (Phillipsburg, NJ). HPLC grade acetonitrile, methanol, 2propanol, chloroform, mono-basic potassium phosphate (KH2PO4), perchloric acid,
phosphoric acid, sulfuric acid, acetone, sodium hydroxide, ammonium hydroxide, trisbase, sodium dodecyl sulfate (SDS), and bovine serum albumin were obtained from EMD
Chemicals Inc. (Gibbstown, NJ). Poly-L-lysine was obtained from MP Biomedicals,
LLC (Solon, OH). Glacial acetic acid, n-hexane, toluene, and all cell culture supplies
were acquired through VWR International, LLC (Batavia, IL). GC grade anhydrous
methanol was from Macron™ Chemicals (Charlotte, NC). Glutaraldehyde,
paraformaldehyde, osmium tetraoxide, uranyl acetate, lead citrate, embed-812 (Epon-812
substitute) WPE #154.3; araldite-502 (modified bisphenol A epoxy); BEEM embedding
capsule size#3; cresyl fast violet C.I.#51180, pre-cleaned Gold Seal micro-slides and
formvar carbon support film specimen 2 x 1 mm slot grids were purchased from Electron
Microscopy Science (Hatfield, PA). All Western blot supplies including acrylamide, bisN,N’-methylene-Bis-acrylamide, N,N,N’,N’-tetramethylene-diamine (TEMED),
ammonium persulfate, 12 and 24 well Criterion Empty Cassettes (#345-9901 and #3459903) were obtained from Bio-Rad Laboratories (Hercules, CA). The complete EDTAfree protease inhibitor cocktail tablets were from Roche Applied Science (Indianapolis,
IN).
Antibodies: Primary antibodies for CD73 (1:1000, sc-14684), CD39 (1:1000, sc18771), A2AR (1:1000, sc-32261), A1R (1:1000, sc-7500), ADK (1:1000, sc-23360),
ADA (1:1000, sc-7451), a-tubulin (1:4000, sc-8035), H3 (1:1000, sc-8654), and
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acetylated- histone H4 (S1/K5/8/12, 1:1000, sc-34263) were obtained from Santa Cruz
Biotech. Inc. (Santa Cruz, CA). Antibodies against acetylated-histone H3 (K9, 1:10,000,
07-352), and histone H4 (1:8000, 04-858) were purchased from Millipore (Billerica,
MA). The HRP-conjugated secondary antibodies: donkey anti-goat IgG (1:10,000, sc2020), goat anti-mouse IgM (1:10,000, sc-2064), goat anti-mouse IgG (1:10,000, sc2005) were purchased from Santa Cruz Biotech. Inc. (Santa Cruz, CA). The goat antirabbit IgG-HRP (1:10,000, 170-5046) antibody was obtained from Bio-Rad Laboratories
(Hercules, CA).

Animals
Male Sprague-Dawley rats were purchased from Harlan Laboratories
(Indianapolis, IN) and experiments were performed following the Guide for the Care and
Use of Laboratory Animals (NIH publication number 80–23) as approved by the
University of North Dakota Animal Care and Use Committee. All rats were allowed to
acclimate for seven days prior to inclusion in the study, maintained on standard
laboratory chow diet, and provided water ad libitum. For studying the effect of singledose acetate supplementation on nucleotide and phosphagen levels, rats weighing 150250 g were given GTA (6 g/kg body weight) by oral gavage while control rats received 6
g/kg body weight water. Rats were anaesthetized with sodium pentobarbital (50 mg/kg,
i.v.) and subjected to head-focused microwave (6 kW, 2s) irradiation at 2, and 4 h posttreatment to immediately stop metabolism. Microwave-fixed brains were flash frozen,
pulverized in liquid nitrogen, and then stored at -80 °C until use. Parallel sets of rats
(100-250 g) used to quantify the effects of long-term acetate supplementation on brain
17

cardiolipin content, neuronal mitochondria, and nucleotide and phosphagen levels
received a daily dose of GTA or water (6 g/kg body weight) for 28 days and were
euthanized 1 h after the last treatment. The 28 day treatment regimen for the
mitochondrial number, and cardiolipin content experiments is based on the 24.4 day halflife of brain mitochondria (Menzies & Gold 1971) and previous results demonstrating a
therapeutic effect of GTA in a rat model of neuroinflammation (Reisenauer et al. 2011).
Rats used for cardiolipin, nucleotide, and phosphagen measurements were euthanized by
head-focused microwave irradiation as described above. Rats used for measuring
neuronal mitochondrial number were anaesthetized using isoflurane (Butler Animal
Health Supply, Dublin, OH) and euthanized by cardiac perfusion with heparinized saline
followed by a mixture of 4 % paraformaldehyde and 2 % glutaraldehyde in 0.1 M
phosphate buffer. Whole brain was removed and post-fixed in the same mixture for 48 h
at 4 ºC after which they were transferred to 0.1 M phosphate buffered saline (PBS, pH
7.4) and stored at 4 ºC until use.

Rat Model of Neuroinflammation
To determine if chronic inflammation alters the long-term effect of acetate
supplementation on brain nucleotides, phosphagens, adenosine metabolizing enzymes
and receptors, rats were subjected to LPS-induced neuroinﬂammation. Male Sprague
Dawley rats weighing between 160 and 180 g (Charles River Laboratories, Portage, MI,
USA) were anaesthetized with 3% isoﬂurane (Butler Animal Health Supply, Dublin, OH,
USA) by continuous inhalation for stereotactic surgery as described (Hauss-Wegrzyniak
et al. 1998a, Hauss-Wegrzyniak et al. 1998b). A cannula (Model 3280PM, Plastics One,
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Roanoke, VA, USA) connected to a subcutaneous osmotic mini-pump (ALZET®, Model
2004, DURECT Corporation, Cupertino, CA) was implanted into the fourth ventricle of
the rat brain. The osmotic pump continuously infused a solution of LPS [5.0 ng/h,
dissolved in artiﬁcial cerebral spinal ﬂuid (aCSF)] or aCSF (Harvard Apparatus,
Holliston, MA, USA) at a steady rate of 0.25 µL/h for a period of 28 days. During this
period rats were treated daily by oral gastric gavage with either 6 g/kg dose of GTA or
water. The rats for nucleotide and phosphagen analysis were divided into four different
groups: group one (n = 5) received an aCSF infusion and treated daily with water for 28
days (aCSF + H2O), group two (n = 4) received an aCSF infusion and daily treatment
with GTA for 28 days (aCSF + GTA), group three (n = 6) received a LPS infusion and
daily treatment with water for 28 days (LPS + H2O) and group four (n = 6) received a
LPS infusion and daily treatment with GTA for 28 days (LPS + GTA). After the 28th day
treatment, rats were anaesthetized, their brains microwave-fixed, pulverized in liquid
nitrogen, and stored at -80 °C as stated above.
The rats used for in vivo adenosine metabolizing enzymes and receptor level
studies were divided into three separate experiments; a 14, and 28 day prophylactic
treatment study, and a 28 day interventional treatment study. During the 14 and 28 day
prophylactic treatment studies, rats were treated daily with water or glyceryl triacetate
(GTA) at a dose of 6 g/kg by oral gavage. In the 28 day interventional study, rats did not
begin receiving daily doses of either water or GTA until 14 days after the start of the LPS
infusion, the time at which neuroglia activation, based on morphological differences, is
significantly elevated above controls (Hauss-Wegrzyniak et al. 1998a). Rats used for
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Western blot analysis were anesthetized with isoflurane, euthanized by decapitation,
brains removed and flash frozen in liquid nitrogen. The post-mortem interval for the
samples did not exceed 1.5 min. Brains samples used for Western blot analysis were
stored at -80 °C until use.

Nucleotide and Phosphagen Extraction from Rat Brain
Nucleotides and phosphagens were extracted using a modified tissue extraction
protocol as described (Hammer et al. 1988). In brief, 10–50 mg pulverized brain sample
was homogenized in ice cold 0.6 M perchloric acid in a pre-cooled Tenbroeck glass
homogenizer then transferred to a micro-centrifuge tube. The homogenizer was then
washed twice with 0.6 M perchloric acid and the combined homogenates were
centrifuged at 13,000 x g at 25 oC for 2 min. The supernatant was neutralized with ice
cold Freon/trioctylamine (4:1, by Vol.) by vortex mixing for 30 sec and the pellet was
saved for protein determination. The neutralized extract was centrifuged at 13,000 x g
for 2 min to induce phase separation and the upper aqueous layer was collected and
stored at 4 °C until analysis. Phosphagens were analyzed within 3 h of extraction and
nucleotides were analyzed within 24 h using high performance liquid chromatography
(HPLC) as outlined below.

Preparation of Nucleotide and Phosphagen Standards
All standard stock solutions were prepared by dissolving 10–25 mg of a pure
nucleotide in 1–1.5 mL of deionized water or 100 mM KH2PO4 buffer (pH 7.5) and
stored at -20 °C until use. Standard solutions were diluted 1000-fold and the absorbance
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was recorded at 259 nm for adenine nucleotides, 253 nm for GTP, and 275 nm for 1, N6ethenoadenosine. The molar concentration of the stock standards was calculated using
the molar extinction coefficients. Stock standards were further diluted in deionized water
or 100 mM KH2PO4 buffer (pH 7.5) to prepare individual (1 or 2 mM) and mixed (50
µM) working nucleotide standards. All calibration procedures were performed using
freshly made stock standards or frozen 1–2 mM aliquots. The working standards were
stored at 4 °C for no more than one month prior to use. The purity of the adenine
nucleotide working standards was determined using HPLC with UV detection described
below and are listed in Table 1. Stock phosphagen standards were freshly prepared (10
mM) on weight bases in deionized water and were diluted appropriately to obtain
working standards for generating standard curves.
Table 1: Percentage purity of individual and mixed stock nucleotide standards
Percentage nucleotide content of standards
Adenosine
AMP
ADP
ATP
Mixture
Adenosine 100.0 ± 0.0 3.5 ± 0.4
103.5 ± 0.4
AMP
96.5 ± 0.4 6.6 ± 0.8
103.1 ± 0.6
ADP
93.4 ± 0.8 2.5 ± 0.3 95.9 ± 1.1
ATP
97.5 ± 0.3 97.5 ± 0.3
Values represent means ± standard deviation (SD, n = 3) expressed as percentage of total
peak area
Quantification of Brain Nucleotides
Nucleotide analysis from rat brain samples was performed using HPLC with UV
detection as described (Hammer et al. 1988) with slight modifications. The separation
was performed on an ISCO HPLC system with an in-line UV detector (model V4) and a
Waters SunfireTM ODS column (5 µm, 250 x 4.6 mm, Milford, MA) equipped with a C18
SecurityGuard cartridge (Torrance, CA). Column temperature was maintained at 40 °C.
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HPLC system was controlled and data analysis was performed using Clarity advanced
chromatography software (Ver. 2.6, DataApex, Prague, Czech Republic). The mobile
phase consisted of buffer A, 30 mM KH2PO4 + 7.5 mM TBAP, pH 5.45; and buffer B,
acetonitrile/30 mM KH2PO4 (1:1, by Vol.) + 7.5 mM TBAP, pH 7.0 (adjusted before
addition of the organic phase). Buffers were filtered using a 0.45-µm Supor-450
membrane filter (Pall Corporation, Ann Arbor, MI) prior to addition of the ion-pairing
reagent (TBAP). The 40 min gradient elution program consisted of 10% buffer B
initially maintained for 0.5 min and then increased to 25% over a period of 8.5 min and
held constant for 2 min. The gradient was then increased to 50% buffer B over 4 min
followed by a gradient to 60% over 19 min. At 34 min the proportion of buffer B was
decreased to 10% over a 4 min period, held constant for 2 min, and the column was
allowed to equilibrate for 20 min before injection of the next sample. The flow rate was
held constant at 1 mL/min throughout the separation and the nucleotide detection was
performed at 260 nm. The peaks were identified by comparison of sample retention
times to known standards. Calibration curves generated based on standard peak area
were used to quantify sample nucleotide levels. The results obtained are expressed as
nmoles of nucleotide per mg of protein.

Quantification of Brain Phosphagens
Phosphagens analysis was performed as described (Dunnett et al. 1991) using the
HPLC and UV detection system described above with a modified solvent and gradient
system, and a Waters Spherisorb® ODS2 column (5 µm, 250 x 4.6 mm Milford, MA).
The mobile phase consisted of buffer A, 14.7 mM KH2PO4 + 2.3 mM TBAP, pH 3; and
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buffer B, acetonitrile/14.7 mM KH2PO4 (1:1, by Vol.) + 2.3 mM TBAP, pH 6.5 (prepared
in the same manner as described for nucleotide analysis). The 35 min elution gradient
was started at 100% buffer A for the first 5 min followed by a gradient increase in buffer
B to 10% over a period of 6 min. At 11 min, the composition of buffer B was increased
to 50% over 5 min and held constant for 5 min. The gradient was returned to 100%
buffer A over 5 min and held constant for 9 min. The column was allowed to equilibrate
for 20 min prior to the next run and the flow rate was held constant at 1 mL/min
throughout the separation. Phosphagen detection was performed at 210 nm and the peaks
were quantified using external calibration standards. The results are expressed as nmoles
of phosphagen per mg protein.
Certain rat brain samples for nucleotide and phosphagen analysis were analyzed
on a System Gold® 125 Solvent Module (Beckman Coulter, Inc., Fullerton, CA)
equipped with a System Gold® 508 autosampler and an in-line System Gold® 168 UV
detector (Beckman Coulter, Inc., Fullerton, CA). The column and separation parameters
were same as mentioned above for nucleotide and phosphagen analysis.

Glycogen Analysis
Whole brain glycogen was measured in microwave-fixed pulverized brain
samples as per the method described by (Cruz & Dienel 2002) with modifications.
Approximately, 50 mg brain powder was homogenized in phosphate buffered saline (pH
7.0) followed by glucose solubilization and glycogen precipitation with ethanol (65% of
total Vol.). The samples were vortex mixed and centrifuged at 13,000 x g at 4 oC for 10
min. The supernatant containing endogenous glucose was discarded and the pellet was
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homogenized in 1.5 mL of 0.03 M hydrochloric acid. Samples were than heated at 90 °C
for 45 min followed by centrifugation at 13,000 x g at 4 oC for 10 min. A 10 µL aliquot
of the supernatant containing glycogen was incubated with amyloglucosidase enzyme to
release glucosyl units which were quantified using a commercial fluorometric kit
(Cayman Chemical Company, Ann Arbor, MI). Basal glucose levels obtained from
samples not incubated with the enzyme served as background and were subtracted from
total glucosyl units released from glycogen. Brain glycogen levels are expressed as µmol
of glucosyl units released per gram brain.

Cardiolipin Analysis
Microwave-fixed and pulverized rat brain samples were extracted in n-hexane: 2propanol (3:2, by Vol.) using a Tenbroeck homogenizer (Hara & Radin 1978). Tissue
extracts and cardiolipin standards, dissolved in chloroform, were isolated on 20 cm x 20
cm TLC Silica gel 60 plates (EMD Chemicals Inc., Gibbstown, NJ) using a two-solvent
system. Solvent A was chloroform/methanol/acetic acid/formic acid/water (70:30:12:4:2,
by Vol.), and Solvent B was n-hexane/di-isopropyl ether/acetic acid (63:35:2, by Vol.).
Two TLC chambers were equilibrated with the solvents for at least 1 h before separation.
Samples and standard were spotted on the plate, dried for 5 min at 85 °C then placed into
the TLC chamber containing solvent A and eluted for 10 cm. The TLC plate was air
dried for 15 min then eluted to the top of the plate with solvent B. Bands were visualized
using either iodine vapors (phosphorus assay) or with a TNS solution (50 mM in 25 mM
Tris buffer, pH 7.4) using UV light (fatty acid analysis). Cardiolipin mass was measured
using a phosphorus assay as described (Rouser et al. 1966) using KH2PO4 dissolved in
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deionized distilled water (0.125–4.0 mM) as standards. The fatty acid composition of
cardiolipin was measured by gas liquid chromatography as described (Long et al. 2010).
Fatty acid standards were used to identify and quantify the fatty acid components in the
samples based on their retention times and concentration factors, respectively. Brain
cardiolipin levels are expressed as nmoles of phosphorus per mg protein and the fatty
acid content of cardiolipin is expressed as nmoles of fatty acid per mg protein and mole
percentage of total fatty acid content.

Electron Microscopy
Brain tissue was embedded in a plastic mold using 12% gelatin and egg yolk (1:2,
by Vol.) then post-fixed in 4% paraformaldehyde/2% glutaraldehyde for 48 h at 4 °C.
Transverse 40 µm sections were isolated from the CA3 region of the hippocampus using
a Vibratome (Bannockburn, IL), and placed in PBS (pH 7.4) at 4 °C. The sections were
incubated in 2% osmium tetraoxide in 0.1M PBS at 37 °C for 45 min, dehydrated with
increasing concentrations of ethanol/propylene oxide, infiltrated overnight in
Epon/Araldite embedding medium (Ted Pella), flat mounted between silanized glass
slides, then polymerized at 60 °C for 72 h. The Vibratome sections embedded in
Epon/Araldite medium were visualized under light microscope to morphologically
identify the stratum pyramidale cell bodies in the CA3 region of the hippocampus and
were glued to an Epon/Araldite bullet for ultrathin sectioning. Ultrathin sections (90–120
nm) were serial mounted on copper (2 x 1 mm) formvar/carbon stabilized slot grids. The
slot grids were stained in a Leica EM AC20 autostainer (Richmond, IL) using 0.5%
uranyl acetate for 30 min followed by 7 min in 3% lead citrate with intermittent water
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rinses. Sections were examined at 60 kV in a Hitachi H-7500 transmission electron
microscope (Pleasanton, CA). Neurons were identified based on size, morphology, and
presence of large nucleoli and their identity was confirmed by presence of synapses and
absence of heterochromatin. Images were collected at 4,000 X and 20,000 X
magnification and digitized with an Epson Perfection V750 PRO scanner (Long Beach,
CA). Total cytosolic area and mitochondrial number from at least twelve CA3 neurons
per animal were quantified. Approximately 10–20 micrographs covering the complete
neuronal soma were integrated with minimum overlap using MCIDTM Analysis 7.0
software (InterFocus Imaging Ltd, UK). All micrographs were coded and analyzed by a
third party blind to the experimental conditions. The results are expressed as total
number of mitochondria per 100 µm2 cytosol.

Rat Brain Extraction for Ecto-5’-nucleotidase Activity
Brains were placed on ice, dissected at the middle carotid artery, and the anterior
portion was placed in a tube containing 3 mL of ice cold extraction buffer (50 mM Tris
buffer (pH 7.4) containing 150 mM sodium chloride, 1 mM EGTA, 1 mM sodium
orthovanadate, 5 mM zinc chloride, 100 mM sodium fluoride, 1 mM PMSF, one
complete, EDTA-free tablet (Roche Applied Science, Indianapolis, IN) per 50 mL, and
0.1% Igepal CA-630). The sample was allowed to sit on ice for 10 min then
homogenized using probe sonication until no solid was evident. Homogenized samples
were centrifuged at 4 °C for 20 min at 4,500 x g and the cytosolic portion was aliquoted
into small volumes and stored at -80 °C until use.
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Ecto-5’-nucleotidase Activity Assay
Sample brain extracts were diluted in ice cold assay buffer [50 mM Tris buffer
(pH 7.4 at 37 °C] containing 20 mM β-glycerophosphate, and 20µM erythro-9-(2hydroxy-3-nonyl) adenine) to a protein concentration of 3.33 µg/µL. Each sample (500
µg protein) was assayed in duplicate, with one assay containing 400 µM α, β-methylene
adenosine 5’-diphosphate in the buffer, as a control to inhibit the activity of CD73.
Samples were pre-incubated at 37 °C for 10 min and the assay was started by adding 1
mM AMP and incubating for 30 min at 37 °C. The reaction was stopped with 3 M
perchloric acid and placed on ice before being centrifuged at 18,100 x g for 5 min at 4 °C.
The adenosine formed by CD73 was then converted into its fluorescent derivative and
quantified using HPLC with fluorescence detection as described below (Bhatt et al.
2012). Adenosine levels from the control reaction were subtracted from the experimental
reaction to calculate CD73 activity in units of nmol adenosine/mg protein/min

Cell culture
Primary astrocyte culture: Primary cortical astrocyte cultures were prepared from
3-4 day old Sprague-Dawley rat pups as described (McCarthy & de Vellis 1980) in
accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication
number 80-23) as approved by the University of North Dakota animal care and use
committee. Briefly, pups were decapitated and brains were dissected out into a petri dish
containing Ca2+/Mg2+free Hanks balanced salt solution (CMF-HBSS, Mediatech Inc,
Manassas, VA). After removing the meninges, cerebral hemispheres were separated and
the cerebellum and white matter were dissected out to isolate the cortical region. Pooled
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cortices from 3–4 rat pups were rinsed with CMF-HBSS, minced and transferred to a
polypropylene tube. To dissociate the cells, the samples were triturated using a glass
pipette and incubated at 37 °C on a shaking water bath for 10 min. The cell suspension
was then centrifuged at 360 x g for 5 min and the cells were re-suspended in DMEM/F12
media (Mediatech Inc, Manassas, VA) containing 15% fetal bovine serum (FBS, PAA
Laboratories Inc, Dartmouth, MA). The cell pellet was triturated into solution then plated
in the ratio of 0.5 brains per 25 cm2 flask (pre-coated with poly-L-lysine) and were
allowed to grow for 7 days in DMEM/F12/10% FBS media supplemented with penicillin
(100 IU/mL), streptomycin (100 µg/mL), amphotericin B (2.5 µg/mL) and HEPES (10
mM) in a humidified incubator with 5 % CO2 (Binder, Tuttlingen, Germany). The cell
culture media was replaced every alternate day throughout the study. On day 8, cells
were transferred to a shaking incubator at 37 °C for 24 h under air-restricted conditions to
remove oligodendrocytes and microglia. Astrocyte-enriched cell cultures were allowed
to grow for another 4 days and then on day 12 the astrocyte cell cultures were divided
onto 100 x 20 mm poly-L-lysine coated culture dishes or 6 well plates using trypsin (BD
and Company, Sparks, MD) at a density of 1.0 x 106 cells/dish or 5.0 x 105 cells/well,
respectively. The enrichment of astrocytes was determined to be greater than 95 % by
GFAP immuno-fluorescence staining as described (Weinstein 2001). At approximately
90% confluence, media was removed and washed three times with CMF-HBSS followed
by appropriate treatment in DMEM/F12 media without serum.
Culturing BV2 microglial cell line: The immortalized murine BV2 microglial cell
line (Bocchini et al. 1992) was obtained from Dr. Colin K. Combs (University of North
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Dakota, Grand Forks, ND). The cells were cryo preserved under liquid nitrogen in
DMEM/F12 media containing 20% FBS and 10% dimethyl sulfoxide (DMSO). Frozen
cultures were thawed, washed with DMEM/F12 media containing 10% FBS to remove
DMSO and cultured in DMEM/F12/10% FBS medium in 100 x 20 mm dishes. BV2
cells at approximately 27th passage were plated in 6 well-plates at a density of 5.0 x 105
cells/well and allowed to reach 80–90% confluence before experimental treatment.
Cell culture treatment: A cell viability assay [lactate dehydrogenase (LDH) assay
as describe below] was conducted with different sodium acetate (NaAc) and sodium
chloride (NaCl) concentrations (8, 12, 16, 32 mM) in primary astrocyte cultures to detect
the highest tolerable dose of acetate. No significant cell death compared to the normal
serum control was observed with 8 and 12 mM NaAc and NaCl. However, at 16 and 32
mM significant LDH release was observed with both NaAc and NaCl demonstrating that
the increase in cell death was due to increase in osmolarity of the medium. Further, the
concentrations (8 and 12 mM) that were devoid of significant cell death bracket the in
vivo levels of brain acetate (8.5 µmol/g brain ~10.6 mM) achieved with a comparable
dose of GTA (5.8 g/kg body weight) in mice (Mathew et al. 2005). Therefore, for our in
vitro experiments we selected a dose of 10 mM NaAc to mimic in vivo acetate
supplementation. Equimolar NaCl served as a control to account for the osmolarity
changes in the culture medium with treatment. BV2 cells or primary astrocytes grown in
6 well plates or 100 x 20 mm dishes (80–90% confluent) were either serum starved for 1–
24 h or directly treated with NaAc/NaCl (5–10 mM) in presence or absence of LPS
(6.25–1000 ng/mL) for 0.25–48 h. For cellular nucleotide, phosphagen, adenosine
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metabolizing enzymes and receptor analysis cultures were treated with 10 mM NaAc
with/without LPS (1000 ng/mL) along with the NaCl control. Cultures used for
extracellular nucleotide analysis were treated with NaCl/NaAc in the presence and
absence of LPS (1000 ng/mL) in HBSS instead of the DMEM/F12 medium. For lipid
analysis, BV2 cells were not serum starved and were treated with 1, 5, and 10 mM NaAc
with/without LPS (6.25 ng/mL) for 2 h.

Lactate Dehydrogenase Assay for Cell Death Determination
Cellular release of lactate dehydrogenase (LDH) enzyme was used to measure cell
viability by using a commercial nonradioactive colorimetric micro plate assay kit
(Clontech Laboratories Inc., Mountain View, CA), according to the manufacturer’s
guidelines. Sample and LDH standard absorbance values were measured at 490 nm with
630 nm as the reference wavelength.

Nucleotide Extraction from Cell Cultures
Following treatment, culture dishes or plates were ﬂash frozen by rapid
immersion in liquid nitrogen. The cells were stored at -80 °C prior to nucleotide analysis.
Frozen cells were scrapped off culture dishes on dry ice and were transferred to a microcentrifuge tube pre-chilled in liquid nitrogen. The frozen cells were homogenized using a
Polytron® PT1200E homogenizer (Kinematica Inc, Bohemia, NY) in 500 µL ice cold 0.6
M perchloric acid to extract the nucleotides. The homogenate was centrifuged at 13,000
x g for 2 min at 4 °C. The supernatant was collected and neutralized with 1 mL ice cold
freon/trioctylamine (4:1, by Vol.). The pellet was saved for protein determination. The
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neutralized nucleotide extract was vortex mixed for 30 sec then centrifuged at 13,000 x g
for 2 min to induce phase separation. The upper aqueous layer was collected and stored
at 4 °C until derivatization for not more than 24 h. For extracellular nucleotides, HBSS
buffer incubated with the cells was collected after several time-points and was directly
mixed with ice-cold perchloric acid (final concentration 0.6 M) to precipitate dissolved
proteins. The extract was centrifuged at 13,000 x g at 25 oC for 2 min and immediately
neutralized with ice cold freon/trioctylamine (4:1, by Vol.). The adenine nucleotides
were derivatized and analyzed using HPLC with fluorescence detection as describe
below.

Quantification of Cell Culture Nucleotides
Adenine nucleotides from the cellular nucleotide extracts or extracellular medium
were converted into respective fluorescent 1, N6-etheno derivatives and quantified using
an ion-pairing HPLC method with fluorescence detection. Briefly, a 50 µL aliquot of the
nucleotide extract was mixed with 150 µL freshly prepared mix of chloroacetaldehyde
(7.8 M) and 1 M acetate buffer (pH 4.5) [11.2: 138.8, by Vol.] in a 13 mm capped glass
tube. Tubes were vortex mixed, centrifuged at 450 x g for 2 min at 22 °C, and then
heated to 60 °C for 60 min in a Techne DRI-Block DB-3A (Techne, Cambridge, UK).
After the reaction, the tubes were immediately placed at 4 °C to stop the reaction,
centrifuged at 450 x g for 2 min at 22 °C and then diluted with water to 1:6 for AMP and
adenosine while a 1:80 dilution was used for ATP and ADP analysis. A 100 µL aliquot
of this solution was placed in a microvial and 50 µL of the derivatized sample was
injected on the HPLC system described below for analysis.
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Etheno-derivatized adenine nucleotides from cell culture samples were analyzed
using a System Gold® 125 Solvent Module (Beckman Coulter, Inc., Fullerton, CA)
equipped with a System Gold® 508 autosampler and an in-line Jasco FP-2020
fluorescence detector (Jasco Corporation, Tokyo, Japan). Separation was performed on a
Waters SunfireTM ODS column (5 µm, 250 x 4.6 mm, Milford, MA) equipped with a C18
SecurityGuard cartridge (Phenomenex, Torrance, CA) at 22o C. HPLC system was
controlled and data analysis was performed using the 32 Karat™ software (Ver. 7.0,
build 1048, Beckman Coulter Inc., Fullerton, CA). The mobile phase consisted of buffer
A, 30 mM KH2PO4 + 0.8 mM TBAP, pH 5.45; and buffer B, acetonitrile/30 mM KH2PO4
(1:1, by Vol.) + 0.8mM TBAP, pH 7.0. The pH of buffer B was adjusted to 7.0 prior to
the addition of acetonitrile. All buffers were filtered using a 0.45-µm Supor-450
membrane filter (Pall Corporation, Ann Arbor, MI) prior to addition of the ion-pairing
reagent (TBAP).
The etheno-adenine nucleotides were eluted using the following gradient. The
initial buffer B concentration was maintained at 10 % for 0.5 min, increased to 20% over
a period of 2.5 min, and then held constant for 4 min. At 7.0 min the concentration of
solvent B was increased to 50% over a 4 min period and then held constant for 10 min.
At 21 min the proportion of buffer B was decreased back to the starting concentration of
10% over a 4 min period and then held constant for 5 min until the end of the run. The
re-equilibration time between samples and the flow rate was held constant at 20 min and
1 mL/min, respectively. The quantification of the etheno-adenine nucleotides was
performed using an excitation wavelength of 280 nm with an output emission wavelength
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set at 410 nm. The identity of etheno-adenine nucleotides were determined by comparing
retention times to known nucleotide standards and were further confirmed by enzymatic
peak shift analysis. Calibration curves were generated using a series of mixed nucleotide
standards (0.15–20.0 pmol) that were derivatized similar to cellular nucleotide extracts.
Linear regression of standard peak areas Vs nucleotide amount was used to quantify
sample nucleotide content, which was normalized to total cellular protein and expressed
as pmol or nmol of nucleotide per mg protein.

Western Blot Analysis
For whole brain protein samples, Western blot analysis was performed on CD73
activity protein extracts. However, for cell culture proteins, cells were washed with PBS,
lysed in radio immuno precipitation assay buffer (50 mM Tris, pH7.5, 150 mM NaCl,
0.1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1mM EGTA,
10 mM sodium fluoride, 1mM sodium orthovanadate, 2.5 mM sodium pyrophosphate
containing 1 Roche protease inhibitor cocktail per 50 mL buffer), sonicated for 1 min,
and centrifuged to collect the soluble protein supernatant. Extracts were stored at -80 °C
until used. Equal amount of protein across samples (10–50 µg/well) was denatured in 2x
Laemmli sample buffer and separated using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (15%) at 80–100 V for 2 h at room temperature. Proteins were
transferred to nitrocellulose membranes on ice at 100 V for 1.5 h and blocked with 5%
milk in tris-buffered saline (20 mM Tris base and 150 mM NaCl, pH 7.5) containing
0.05% Tween (TBS-T). Blots were incubated overnight with primary antibodies
(1:1000) at 4 °C, washed four times in TBS-T and incubated with secondary antibodies
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(1-10,000) at room temperature. Protein bands were visualized with a SuperSignal®
West Pico and/or Femto enhanced chemiluminescent substrate (Pierce, Rockford, IL)
using a UVP Bioimaging System (Upland, CA). Image capturing and analysis was
performed with LabWorksTM imaging software (version 4.5.0, UVP Inc., Upland, CA)
and VisionWorksLS analysis software (version 6.3.1, UVP LLC, Upland, CA),
respectively. Optical density of α-tubulin was used for normalization of proteins except
acetylated H3 and H4 which were normalized to total H3 or H4 histones. All Western
blot data are expressed as fold change over controls.

Lipid Extraction from BV2 Cell Culture
Lipids from cultures treated with NaCl or NaAc in presence or absence of LPS
were extracted by the n-hexane: 2-propanol (3:2, by Vol.) method (Hara & Radin 1978).
BV2 cells grown in 6 well plates were washed in PBS and immediately frozen by placing
the plate on liquid nitrogen to minimize fatty acid hydrolysis due to acylhydrolase
activation. Cells were scrapped on dry ice after addition of 2 mL 2-propanol to the
frozen plates and the suspension was transferred to a 16 mm tube. The wells were
washed with 2 mL 2-propanol and was combined with the initial suspension. The
suspension was vortex mixed after addition of 6 mL n-hexane (3:2, n-hexane: 2-propanol
by vol.) and the cellular protein was separated by centrifugation at 4,750 x g for 10 min
(Allegra X-15R, Beckman Coulter Inc., Fullerton, CA). The supernatant was collected
into a 16 mm tube and the pellet was washed with 4 mL n-hexane: 2-propanol (HIP, 3:2
by vol.) by vortex mixing. After centrifugation the supernatant was combined with the
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previous extract and the pellet was saved for protein analysis. Extracts were stored at -20
°C until analyzed.

Quantification of Fatty Acids from BV2 Cell Cultures
The BV2 cell lipid extract was concentrated to zero by evaporating the solvent
under nitrogen at 65 °C and brought up in 4 mL HIP. The extracts were concentrated to
zero and brought up in 2 mL chloroform. A 1 mL aliquot was transferred to a 16 mm
tube for acid catalyzed fatty acid methyl esters (FAME)-derivatization as described
(Akesson et al. 1970). The samples were mixed with 50 µL of internal standard (methyl
heptadecanoate, methyl-17:0, 276.1 pmol/µL) and concentrated to zero as above. Dried
samples were mixed with 4 mL 2% sulfuric acid in toluene: methanol (1:1, by Vol.),
vortex mixed and incubated at 65 °C for 2 h with shaking at 120 rpm in a water bath.
The tubes were cooled at 4 °C for 5 min and the samples were immediately neutralized
with 4 mL 5% ammonium hydroxide solution in water. Neutralized FAME were
extracted three times with 3 mL n-hexane, collected in a 16 mm tube and concentrated to
zero by evaporating n-hexane at 45 °C under nitrogen. The FAME were transferred to
microvials by dissolving in three 100 µL aliquots followed by concentration to zero using
a SpeedVac and reconstituted in 50 µL n-hexane. A 1–4 µL aliquot was analyzed on a
Shimadzu GC-2010 gas chromatograph equipped with a flame ionization detector using a
SP™-2330 capillary column (30 m x 0.32 mm x 0.2 µm film thickness; Supelco,
Bellefonte, PA). Detector and injection temperatures were maintained at 220 °C and
helium was used as a carrier gas with a constant flow velocity of 30 cm/s. Initial column
temperature was maintained at 175 °C for 7 min followed by a gradient increase at 3 °C
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per min to 200 °C and held constant for 9.5 min. Fatty acid standards were used to
identify and quantify the fatty acids in the samples based on their retention times and
concentration factors, respectively using the Simadzu EZStart software (build 14, version
7.2.1 SP1, Kyoto, Japan). Fatty acid standards were used to identify and quantify the
fatty acids in the samples based on their retention times and concentration factors,
respectively.

TLC Separation and Phospholipid Analysis
Cellular lipid extracts, dissolved in chloroform, were isolated on 20 cm x 20 cm
TLC Silica gel 60 plates (EMD Chemicals Inc., Gibbstown, NJ) using
chloroform/methanol/glacial acetic acid/water (50:37.5:3:2, by Vol.) solvent system
(Jolly et al. 1997). Samples and standard were spotted on heat activated plates, dried for
5 min at 85 °C then placed into the TLC chamber that was pre-equilibrated with the
solvent system for at least 1 h. The solvent front was allowed to reach the top of the plate
after which the plates were air dried and bands were visualized using iodine vapors.
Sample bands corresponding to the phospholipid standards were scraped and placed in
acid washed tubes for phosphorus assay. Total phospholipid mass was measured by
quantifying the phosphorus content of the TLC separated sample bands as described
(Rouser et al. 1966) using KH2PO4 dissolved in deionized distilled water (0.03–1.0 mM)
as standard at 797 nm. The sample phospholipid content for each class is expressed as
nmoles of phosphorus per mg total cellular protein.
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Cholesterol Assay
Cholesterol levels in BV2 cell lipid extracts were measured by a method describe
by (Bowman & Wolf 1962). One half of the lipid extract dissolved in chloroform was
transferred to a test tube and dried to zero under nitrogen at 45 °C. The dried sample was
dissolved in 500 µL ethanol (200 proof) and 500 µL of freshly prepared 0.2 % ferric
chloride in sulfuric acid containing 8% phosphoric acid was slowly added. Samples were
vortex mixed for 5 min and centrifuged until the samples reached room temperature. The
cholesterol content was determined by measuring sample and standard cholesterol (0.94–
120 µg) absorbance at 550 nm. Total cholesterol content was normalized to total cellular
protein and is expressed as µg cholesterol per mg protein.

Protein Analysis
Protein pellets from nucleotide, phosphagen, and cardiolipin analysis were
washed with acetone, dried using a nitrogen evaporator and then re-suspended for 24 h in
1 mL 1 M sodium hydroxide. The dissolved pellets were boiled for 5 min and protein
content was measured as described (Bradford 1976) using bovine serum albumin as
protein standard. The total protein present in the sample was expressed as mg of total
tissue or cellular protein and was used for normalizing metabolite levels. For protein
analysis from cell culture lipid extracts the protein pellet was dried over night at 55 °C in
an oven. Dried protein pellet was heated in 2 mL 0.2 M potassium hydroxide at 65 °C
for 24 h in a water bath followed by Bradford protein estimation. The protein
concentration of samples used for the Western blot analysis was measured directly from
the cellular protein extracts.
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Statistical Analysis
All the data are expressed as means ± standard deviation (SD) with a sample size
of 5–10 animals/cultures per group unless specified differently. Statistical analysis for
single–dose GTA administration experiments was performed using a Kruskal–Wallis
nonparametric ANOVA followed by Dunn’s post hoc test for multiple comparisons. For
the 28 day cardiolipin, fatty acid content, neuronal mitochondria, nucleotide, and
phosphagen analysis and interventional acetate supplementation studies the treatment
group was compared to control using an unpaired, two-tailed, Mann–Whitney U-test. For
28 day acetate supplementation in the neuroinflammation model for nucleotide and
phosphagen analysis, 14 and 28 day prophylactic treatments, in vitro Western blot, fatty
acid content, phospholipid, and cholesterol analysis a one way parametric ANOVA with
Tukey’s post hoc test was performed for multiple comparisons. The statistical
signiﬁcance was set at p ≤ 0.05 and the analysis was performed using GraphPad InStat
statistical software (Ver. 3.10, San Diego, CA) and graphs were prepared using
SigmaPlot graphical software (version 10.0, build 10.0.1.25, Systat Software, Inc., San
Jose, CA)
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CHAPTER III
RESULTS
Single-dose acetate supplementation reduces brain AMP levels without altering
other nucleotides
Because acetate supplementation is thought to stimulate brain bioenergetics by
increasing acetyl-CoA metabolism, we measured brain nucleotide levels in control rats
and rats treated with GTA for 2, and 4 h. Using HPLC, we found that there were no
differences in brain ATP (21.4 ± 2.6 to 24.3 ± 2.6 nmoles/mg protein, Figure 2A), ADP
(15.3 ± 3.4 to 17.9 ± 1.1 nmoles/mg protein), NAD (5.6 ± 0.8 to 6.6 ± 0.7 nmoles/mg
protein), or GTP (4.9 ± 0.5 to 5.7 ± 1.0 nmoles/mg protein) levels. The control
nucleotide values observed in this study are comparable to the reported values obtained
using 6 kW (2 sec) microwave irradiation to stop brain metabolism (Delaney & Geiger
1996). On the other hand, brain AMP levels were significantly decreased at 4 h
following treatment (5.4 ± 0.8 to 3.6 ± 1.2 nmoles/mg protein, Figure 2B). The
calculated energy charge ratio [ECR, (ATP + ½ ADP) / (ATP + ADP + AMP)], which
incorporates the complete adenylate pool remained unchanged between GTA treated
(0.73 ± 0.06) and control rats (0.70 ± 0.02). The lack of changes in the ECR can be
explained by the relatively smaller proportion of AMP compared to ATP and ADP. To
further substantiate these findings nucleotide stability and recovery studies were
performed using radio-labeled ATP, ADP, and AMP. Figure 3A depicts the separation
of the different nucleotides from brain tissue samples. The separation was reproducible
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with average retention times of 9.4 ± 0.2, 14.0 ± 0.2, 23.4 ± 0.1, 29.5 ± 0.2, and 31.5 ±
0.2 min for NAD, AMP, ADP, GTP, and ATP, respectively. Nucleotide standards
showed a linear relationship between nucleotide amount and peak area over the range of
6.25–400 µM and were stable for at least 3 months at 4 °C. Radioactively labeled [14C]
ATP, [14C] ADP, and [14C] AMP (90, 98, and 97% pure) were used to measure the
extraction recovery of adenine nucleotides. Known amounts of radioactivity was added
to the sample before extraction, the corresponding peaks after elution were collected, and
the nucleotide recovery was measured using liquid scintillation counting (LS 6500,
Beckman Coulter, Fullerton, CA). The total nucleotide recovery was 103.4 ± 3.2% and
the individual recoveries for ATP, ADP, and AMP were 103.2 ± 2.4%, 103.1 ± 5.1%, and
112.0 ± 3.1% (n=6), respectively. This data suggests that the extraction of nucleotides
was complete and extraction loss was minimal.

Single-dose acetate supplementation increases brain phosphocreatine levels
Because adenine nucleotides are tightly regulated by negative feedback
mechanisms, under normal conditions their levels remain stable (Wallimann et al. 1992).
Therefore, if acetate is utilized in the TCA cycle the generated energy is conserved in the
form of PCr (Meyer et al. 1984). Thus, creatinine (Cn), Cr, and PCr (phosphagen)
analysis was performed to determine the effect that acetate supplementation has on
stimulating brain energy reserves using HPLC. We found that acetate supplementation
significantly increased brain PCr levels (Figure 4) and the PCr/Cr ratio at 4 h (0.54 ±
0.07) compared to control (0.39 ± 0.06). We found no difference in the concentration of
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Figure 2: Single-dose acetate supplementation reduces brain AMP levels without altering ATP levels.
Quantification of brain ATP (Panel A) and AMP levels (Panel B) in control, and GTA-treated rats that were subjected to microwave
fixation at 2, and 4 h post GTA treatment. Data represent mean ± SD (nmol/mg protein), n= 8, 7, and 9 for Control, 2, and 4 h post
GTA treatment, respectively. Statistical analysis was performed using Kruskal-Wallis nonparametric ANOVA followed by Dunn’s
post hoc test and the statistical significance is reported comparing treatment duration to control values (*, p < 0.05 ).

Figure 3: Representative HPLC chromatograms for nucleotide and phosphagen
analysis from brain tissue.
Panel A illustrates the elution order of nucleotides (NAD, AMP, ADP, GTP, ATP) and
Panel B shows elution order of phosphagens (Cn, Cr, PCr) from microwave-fixed brains.
Abbreviations are: ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP,
adenosine monophosphate; GTP, guanosine triphosphate; NAD, nicotinamide adenine
dinucleotide; PCr, phosphocreatine; Cr, creatine; and Cn, creatinine. Solid lines
represent the absorbance measured at 260 nm (Panel A) and 210 nm (Panel B) and the
dashed line represent the gradient of buffer B (percent of total).
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brain Cr and Cn levels being 106.3 ± 13.7 to 119.5 ± 7.7, and 4.0 ± 0.4 to 4.8 ± 1.1
nmoles/mg protein, respectively. In this separation, the concentration of the ion-pairing
reagent (TBAP) was reduced to 2.3 mM. The addition of TBAP or the gradient elution
did not affect the phosphagen separation. However, both were essential to increase the
retention time and ensure complete resolution of the phosphagens from sample
contamination and other nucleotides (Figure 3 B). The averaged retention times of Cn,
Cr, and PCr in brain tissue samples were 2.2 ± 0.0, 2.9 ± 0.0 and 6.5 ± 0.0 min,
respectively. Phosphagen standards were prepared in water and a linear response was
observed over the range of 37.50–1200 µM for Cr and 18.75–600 µM for Cn and PCr.

Figure 4: Single-dose acetate supplementation increases brain phosphocreatine
levels.
Quantification of brain PCr levels in control and GTA-treated rats that were subjected to
microwave fixation at 2, and 4 h post treatment. Abbreviations are: PCr,
phosphocreatine. Data represent mean ± SD (nmol/mg protein), n= 8, 7, and 9 for
Control, 2, and 4 h post GTA treatment, respectively. Statistical analysis was performed
using Kruskal-Wallis nonparametric ANOVA followed by Dunn’s post hoc test and the
statistical significance is reported comparing treatment duration to control values (*, p <
0.05 ).
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Single-dose and long-term acetate supplementation do not alter brain glycogen
content
Another energy reserve available to the brain is astrocytic glycogen. During
acetate supplementation, preferential utilization of acetate by astrocytes (Waniewski &
Martin 1998) may result in reduced glucose utilization or channeling of unused glucose
to glycogen synthesis. Under increased metabolic demand astrocytes support neuronal
energy metabolism through glycogenolysis and increasing the availability of glucose for
neurons (Dinuzzo et al. 2012). Thus, brain glycogen levels were measured after 4 h of
single GTA dose and 28 days of daily GTA administration. No significant changes were
found in brain glycogen levels with 4 h (4.02 ± 0.67 µmol/g) and 28 day GTA (4.12 ±
0.73 µmol/g) administrations as compared to respective controls (3.78 ± 0.84 and 3.77 ±
0.95 µmol/g). The whole brain glycogen levels obtained in this study are comparable to
published values found in other animal models (3.3–12 µmol/g) (Choi & Gruetter 2003,
Cruz & Dienel 2002, Herzog et al. 2008, Morgenthaler et al. 2009). Regional variation
in brain glycogen levels do occur with highest levels found in pons/medulla and
cerebellum and lowest in cortex and striatum (Brown 2004, Herzog et al. 2008, Kong et
al. 2002). Grey matter is also known to have higher glycogen content compared to white
matter (Brown 2004).

Long-term acetate supplementation does not alter hippocampal neuron
mitochondrial number or whole brain cardiolipin content
It has been shown that 4 weeks of ketogenic diet treatment in rats increases the
number of mitochondria in hippocampal neurons (Bough et al. 2006, Nylen et al. 2009).
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Since the primary effect of both, ketogenic diet and acetate supplementation is thought to
be through increasing acetyl-CoA metabolism we measured the effect that long-term
acetate supplementation had on mitochondrial biogenesis. Thus, we quantified
mitochondrial number in hippocampal neurons (CA3 region) of rats treated with GTA or
water for 28 days using electron microscopy. A representative electron micrograph of a
hippocampal neuron in the CA3 region at a magnification of 4,000 X and 20,000 X is
shown in Figures 5A and 5B, respectively. Quantification of these images showed that
there was no change in the number of neuronal mitochondria per 100 µm2 area when
comparing controls to GTA-treated rats (Figure 5C). To further quantify global changes
in brain mitochondrial mass, we measured whole brain cardiolipin levels and cardiolipin
fatty acid content in rats treated with either water or GTA daily for 28 days. In
eukaryotes, cardiolipin is exclusively found in the inner mitochondrial membrane and
thus can be utilized as a marker for new mitochondrial synthesis (Schlame 2007, Daum
1985). We found that 28 day GTA treatment did not alter brain cardiolipin content
compared to control rats (Figure 5D). Further, treatment with GTA did not alter the fatty
acid content of mitochondrial cardiolipin as determined using gas-liquid chromatography
(Table 2). Collectively, these data suggest that acetate supplementation unlike the
ketogenic diet has no effect on neuronal mitochondrial biogenesis.

Long-term acetate supplementation does not alter nucleotide or phosphocreatine
levels in normal rats
As we had found that a single oral dose of GTA increases PCr levels with a
reduction in AMP levels, we examined the effect that long-term acetate supplementation
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Figure 5: Long-term acetate supplementation does not alter mitochondrial biogenesis.
Panel A shows a representative electron micrograph of a hippocampal CA3 neuron at 4,000X, and Panel B represents a 20,000 X
magnification of the marked region in Panel A. Arrows indicate examples of mitochondria contained within this marked region.
Panel C shows the quantification of mitochondria found in a 100 µm2 cytosol area (n=5) and Panel D shows the quantification of total
cardiolipin levels in control and GTA-treated rats (n=6, 10, respectively). Data presented as the mean ± SD. Statistical analysis was
performed using two-tailed unpaired Mann-Whitney U-test with the threshold for statistical significance set at p ≤ 0.05.

Table 2: Brain cardiolipin fatty acid content in control and GTA-treated rats.
Fatty Acid

Control

GTA-treated

Control

nmol/mg protein
Palmitate (PAM, 16:0)

GTA-treated
Mole %

34.6 ± 4.4

35.9 ± 7.5

9.0 ± 2.8

9.1 ± 1.5

62.2 ± 13.0

61.2 ± 10.4

15.4 ± 1.8

15.7 ± 3.1

106.0 ± 30.7

114.8 ± 28.7

25.7 ± 4.6

28.4 ± 3.3

23.3 ± 6.4

23.0 ± 8.0

5.8 ± 1.2

5.6 ± 1.5

γ- Linolenate (18:3 n-6)

5.5 ± 0.9

4.9 ± 0.8

1.4 ± 0.4

1.3 ± 0.4

Eicosenoate (20:1 n-9)

10.1 ± 3.0

9.0 ± 2.1

2.6 ± 0.8

2.3 ± 0.5

5.0 ± 1.2

4.9 ± 1.1

1.2 ± 0.2

1.2 ± 0.1

53.7 ± 23.7

54.8 ± 20.0

12.7 ± 4.9

13.3 ± 3.2

Lignocerate (24:0)

4.5 ± 2.1

4.3 ± 1.5

1.0 ± 0.4

1.1 ± 0.5

Adrenate (22:4 n-6)

8.2 ± 3.1

6.1 ± 3.3

2.0 ± 0.5

1.5 ± 0.6

Nervonate (24:1 n-9)

4.2 ± 0.7

3.8 ± 0.7

1.1 ± 0.2

1.0 ± 0.2

20.0 ± 9.4

18.5 ± 8.0

4.6 ± 2.0

4.5 ± 1.4

Stearate (STA, 18:0)
Oleate (OLA, 18:1 n-9)
Linoleate (LNA, 18:2 n-6)
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Dihomo-γ-linolenate (DGLA, 20:3 n-6)
Arachidonate (ARA, 20:4 n-6)

Docosahexaenoate (DHA, 22:6 n-3)

Total fatty acid content
404.5 ± 75.9
399.3 ± 79.5
Values represent the means ± SD from control (n = 6) and GTA-treated (n = 10) rats in units of nmol/mg protein and mole percent.

has on brain nucleotides and PCr levels. In rats that were treated daily with an oral
gavage of 6 g/kg GTA or water for a period of 28 days, acetate supplementation was
neither able to elevate brain PCr levels (Figure 6D) nor reduce AMP levels (Figure 6B).
Other nucleotide levels (ATP, Figure 6A; NAD and GTP not shown) and the energy
charge ratio (Figure 6C) as with the single oral dose of GTA were unaltered. These
findings were rather surprising and stimulated us to investigate the effects of long-term
acetate supplementation in a rat model of neuroinflammation.

Long-term acetate supplementation does not alter nucleotide or phosphocreatine
levels in rats subjected to LPS-induced neuroinflammation
Since loss of energy has been linked to various neurodegenerative disorders and
neuroinflammation (Block et al. 2007, Di Filippo et al. 2010, Di Filippo et al. 2006), we
investigated whether chronic inflammation and acetate supplementation can alter brain
nucleotide and PCr levels. Nucleotide and phosphagen levels were measured in
microwave-fixed brain from rats subjected to LPS-induced neuroinflammation that were
treated daily with 6 g/kg GTA or water for 28 days. We found no differences in brain
ATP (11.0 ± 2.2 to 13.9 ± 3.3 nmoles/mg protein), ADP (12.3 ± 0.3 to 16.6 ±2 .9
nmoles/mg protein), AMP (3.0 ± 0.4 to 3.8 ± 0.8 nmoles/mg protein), ECR (0.65 ± 0.03
to 0.65 ± 0.04), NAD (1.5 ± 1.0 to 3.4 ± 2.5 nmoles/mg protein), GTP (2.2 ± 0.8 to 3.1 ±
0.8 nmoles/mg protein), PCr (8.6 ± 4.0 to 21.3 ± 13.3 nmoles/mg protein), Cr (119.9 ±
8.3 to 159.9 ± 25.4 nmoles/mg protein), or Cn (5.9 ± 0.6 to 8.6 ± 1.7 nmoles/mg protein)
levels. Collectively, these data show that long-term acetate supplementation does not
alter nucleotide or PCr levels in a rat model of neuroinflammation. However, GTA
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Figure 6: Long-term acetate supplementation does not alter brain nucleotide or phosphocreatine levels in normal rats.
Quantification of brain ATP (Panel A), AMP levels (Panel B), energy charge ratio [{ATP+(0.5*ADP)}/(ATP+ADP+AMP), Panel C],
and phosphocreatine levels (PCr, Panel D) in control and GTA-treated rats, that were subjected to microwave fixation after 28 days of
treatment. Data represent mean ± SD, n= 6, and 10 for control, and 28 day post GTA treatment, respectively. Statistical analysis was
performed using two-tailed unpaired Mann-Whitney U-test with the threshold for statistical significance set at p ≤ 0.05.

treatment for 28 days during LPS-induced neuroinflammation attenuates neuroglia
activation (Reisenauer et al. 2011) and nucleotides play a crucial role in regulating
inflammation (Di Virgilio et al. 2009b). Therefore, we proposed that during long-term
acetate supplementation brain may adapt to continuously elevated acetyl-CoA levels by
altering purine nucleotide metabolism.

Long-term acetate supplementation alters the levels of adenosine metabolizing
enzymes and receptors in a rat model of neuroinflammation
Purine nucleotides in addition to being energy storage units are important
signaling molecules in the brain (Burnstock 1997). Both ATP and its breakdown product
adenosine are key molecules that modulate the inflammatory response in brain (Di
Virgilio et al. 2009a). Adenosine levels in the brain are a 1000-fold lower than adenine
nucleotides and a delay in brain fixation by a few seconds can result in nucleotide
breakdown elevating adenosine level by a 1000-fold. Hence, accurate quantification of
brain adenosine levels that resemble physiological levels is a daunting challenge. An
alternative approach to determine whether acetate supplementation alters purine
metabolism, increases adenosine formation or enhances the effects of physiological
adenosine was to quantify alterations in adenosine metabolizing enzymes and adenosine
receptors.
To test the hypothesis that acetate supplementation modulates brain adenosine
metabolizing enzymes (ecto-5’-nucleotidase, CD73 and adenosine kinase, AK) and
adenosine A2A receptor levels, we measured the levels of these proteins and the activity of
CD73 in three parallel studies. In studies one and two, rats were subject to
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neuroinflammation for either 14 or 28 days and received prophylactic acetate
supplementation throughout the duration of the experiment. A third study was performed
in which a group of rats were subjected to 28 days of neuroinflammation then treated
using an interventional strategy in which acetate supplementation was started on day 14
following the start of the LPS infusion.
14 day prophylactic acetate supplementation: We measured the levels of CD73,
AK, and A2AR and the activity of CD73 in rats after a 14 day study period. In this study,
there were three groups of rats. Group one received sham surgery with aCSF infusion
and oral water which served as the control group (n = 6), group two received a LPS
infusion dissolved in aCSF with oral water (n = 12), and group three received LPS and
were treated with daily oral doses of GTA (6 g/kg body weight) (n = 6). Protein bands
for CD73, AK, A2AR, and α-tubulin corresponding to molecular weights 45, 41, 42, and
52 kDa (Figure 7A) respectively, were quantified using Western blot analysis. We found
that LPS significantly reduced CD73 levels by 38%, while rats that received LPS plus
GTA did not differ from controls (95% ± 11) (Figure 7B). Since CD73 is the ratelimiting enzyme for adenosine formation and changes in its activity are observed in
inflammatory conditions (Brisevac et al. 2012), CD73 activity was measured in these
samples. The activity of CD73 did not significantly differ between control and rats
subjected to neuroinflammation. However, rats receiving LPS plus GTA had a
significant increase in activity by 31% compared to controls and rats subjected to LPS
(Figure 7C). Further, no significant differences in AK levels were observed between
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Figure 7: Fourteen day prophylactic acetate supplementation alters CD73 levels,
CD73 activity, and A2A receptor levels.
Panel A shows representative images of the Western blot analysis for ecto-5’nucleotidase (CD73), adenosine kinase (AK), adenosine A2A receptor (A2AR), and αtubulin. Panel B and C show CD73 levels and CD73 activity, while Panel D and E show
AK levels and A2AR levels, respectively. All values represent the means ± SD, n= 6, 12,
6 for aCSF+H2O, LPS+H2O, and LPS+GTA groups respectively. Statistical analysis was
performed using one way parametric ANOVA with Tukey’s post hoc test and the
threshold for statistical significance set at p ≤ 0.05. The symbol “a” represents a
difference compared to the aCSF group and “b” represents a difference compared to the
LPS group.
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groups (Figure 7D). Based on these data, we measured A2AR levels and found that LPS
infusion causes a significant increase of 50% compared to controls, while acetate
supplementation prevented the LPS-induced increase leaving A2AR at control levels
(Figure 7E). These results demonstrate that prophylactic acetate supplementation has the
capacity to prevent LPS-induced changes in CD73 and A2AR levels, and is also able to
increase CD73 activity. Although it is not clear whether acetate supplementation
achieves an increase in CD73 activity through changes in gene expression or enzyme
modification, both may be involved. These data do however suggest that acetate
supplementation can modulate adenosine metabolizing enzymes and A2AR levels.
28 day prophylactic acetate supplementation: A 28 day study was performed to
examine the effects of acetate supplementation on brain adenosine metabolizing enzymes
(CD73 and AK) and A2AR levels. The infusion and treatment groups were identical to
those described above in the 14 day prophylactic study except that the GTA treatment
and LPS infusion were continued for 28 days. In this study, we found that LPS
significantly reduced CD73 levels by 28% of controls, which was not evident in rats that
received acetate supplementation (Figure 8B). There was no difference in CD73 activity
between controls and rats subjected to neuroinflammation, but LPS-treated rats receiving
acetate supplementation showed a significant increase in activity (46%) compared to
controls and rats subjected to neuroinflammation (Figure 8C). LPS infusion resulted in a
significant increase in AK levels (43%) compared to control rats. We found no change in
AK levels in rats subjected to neuroinflammation and treated with prophylactic acetate
supplementation (Figure 8D). No difference in A2AR levels was observed between
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Figure 8: Twenty eight day prophylactic acetate supplementation alters CD73
levels, CD73 activity, and AK levels.
Panel A shows representative images of the Western blot analysis for ecto-5’nucleotidase (CD73), adenosine kinase (AK), adenosine A2A receptor (A2AR), and αtubulin. Panel B and C show CD73 levels and CD73 activity, while Panel D and E show
AK levels and A2AR levels, respectively. All values represent the means ± SD, n= 6, 12,
6 for aCSF+H2O, LPS+H2O, and LPS+GTA groups respectively. Statistical analysis was
performed using one way parametric ANOVA with Tukey’s post hoc test and the
threshold for statistical significance set at p ≤ 0.05. The symbol “a” represents a
difference compared to the aCSF group and “b” represents a difference compared to the
LPS group.
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groups (Figure 8E). These results demonstrate that acetate supplementation is able to
prevent LPS-induced changes in CD73 and AK levels, and increase CD73 activity using
a 28 day prophylactic treatment strategy. Collectively, these studies suggest that
neuroinflammation modulates adenosine metabolizing enzymes which can be prevented
with prophylactic acetate supplementation.
Interventional acetate supplementation: The effect of interventional acetate
supplementation (starting at 14 days post LPS infusion until the 28th day of LPS infusion)
on adenosine metabolizing enzymes (CD73 and AK) and A2AR levels was examined.
Treatment with GTA was begun on day 14 because this is the earliest time when
neuroglia activation, based on significant morphological changes in astrocytes and
microglia, has been documented (Hauss-Wegrzyniak et al. 1998a) in this model.
However, the inflammatory signaling starts as early as 6 days following LPS infusion
(Lee et al. 2004). LPS-treated rats receiving an interventional acetate treatment showed a
significant increase in CD73 levels (67%) when compared to rats that received water
(Figure 9B) but demonstrated a significantly lower CD73 activity (88%, Figure 9C).
There was no significant difference in AK levels between rats receiving water and rats
receiving acetate supplementation (Figure 9D). Interventional acetate supplementation
resulted in a significant increase in A2AR levels (155%) compared to controls (Figure
9E). These results demonstrate that acetate supplementation is able to modulate CD73
and A2AR following an interventional treatment strategy. While an increase in CD73
activity was not correlated to an increase in CD73 protein levels as seen with

55

Figure 9: Interventional acetate supplementation alters CD73 levels, CD73 activity,
and A2A receptor levels.
Rats were infused with LPS and were divided into two groups; beginning treatment with
water or GTA beginning on day 14. Panel A shows representative images of the Western
blot analysis for ecto-5’-nucleotidase (CD73), adenosine kinase (AK), adenosine A2A
receptor (A2AR), and α-tubulin. Panel B and C show CD73 levels and CD73 activity,
while Panel D and E show AK and A2AR levels, respectively. Data represent mean ± SD,
n=8, 6 for LPS+H2O and LPS+GTA groups, respectively. Statistical analysis was
performed using unpaired student t-test. The asterisk (*) represents statistical difference
compared to LPS + H2O group (p ≤ 0.05).
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prophylactic treatment, it may be that the mechanism by which acetate exerts its effects
takes longer to alter the activity of the enzyme.

Acetate alters the levels of adenosine metabolizing enzymes and adenosine receptors
in LPS-stimulated BV2 microglia but not in primary astrocytes
In brain, the innate immune response is initiated by microglia and amplified by
astrocytes, which through glial communication act to propagate the neuroinflammatory
response. Since both microglia and astrocytes possess purinergic (P1 and P2) receptors
and the enzymes that regulate extracellular ATP and adenosine levels, they both are
important modulators of purinergic signaling (Di Virgilio et al. 2009b). Based on our in
vivo results demonstrating that acetate supplementation reverses LPS-induced modulation
of adenosine metabolizing enzymes and receptors, we used BV2 microglia and primary
astrocyte cultures to identify the specific cell types responsible for the observed in vivo
changes. Both BV2 microglia and primary astrocytes were divided into four groups:
group one, 10 mM sodium chloride (NaCl, osmolarity control); group two, 10 mM
sodium acetate (NaAc, drug effect); group three, 10 mM NaCl plus 1000 ng/mL LPS
(NaCl+LPS, inflammation group); and group four, 10 mM NaAc plus 1000 ng/mL LPS
(NaAc+LPS, treatment group). Experiments were conducted for 12, 24, and 48 h in both
cell types and levels of enzymes involved in adenosine metabolism, adenosine kinase
(AK) and adenosine deaminase (ADA); enzymes involved in adenosine formation, ecto5’-nucelotidase (CD73) and ecto-apyrase (CD39); and adenosine receptors, A1 and A2A
were analyzed using Western blot analysis.
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BV2 microglia: With regard to enzymes involved in adenosine formation we
found that at 48 h, LPS did not alter CD39 protein levels (Figure 10A and 10B) but
increased CD73 levels to 2-fold (Figure 10C and 10D) above controls. Acetate
prevented the LPS-induced increase in CD73 levels (Figure 10C and 10D) and
decreased CD39 levels (Figure 10A and 10B) to 0.5-fold below control (NaCl) levels.
On the other hand, the levels of enzymes involved in adenosine metabolism, AK and
ADA, were increased to 2- and 1.3-fold by LPS (Figure 11) and acetate prevented the
increase in AK levels (Figure 11A and 11B) while reduced ADA levels (Figure 11C
and 11D) to 0.5-fold below control levels. Further, LPS increased the levels of
adenosine A1 (Figure 12A and 12B) and A2A (Figure 12C and 12D) receptors to 1.5and 2-fold compared to controls while acetate reduced A1 receptor levels by 0.7-fold
below controls (Figure 12A and 12B) and prevented the increase in A2A receptor levels
by LPS (Figure 12C and 12D). No significant changes were observed in any of the
adenosine metabolizing enzymes or adenosine receptors at 12 and 24 h of treatment. Our
results on AK levels and A2A receptors in BV2 microglia are similar to what we found in
vivo, however the CD73 levels are in complete contrast to our in vivo findings. The
discrepancy between the in vivo and in vitro findings may be due to the differential
expression of enzymes and receptors by different brain cell types and their relative
contribution to whole brain analysis. Nonetheless, our results suggest that acetate
supplementation can reverse LPS-induced alterations in adenosine metabolizing enzymes
and receptors in BV2 microglia.
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Figure 10: Acetate reduces CD39 levels and prevents LPS-induced increase in CD73 levels in BV2 microglia.
Cultures were stimulated with 1000 ng/mL LPS for 48 h and ecto-apyrase (CD39, converts ATP and ADP to AMP, Panel A and B)
and ecto-5’-nucleotidase (CD73, converts AMP to ADO, Panel C and D), enzymes were analyzed. Data represent mean ± SD, n ≥ 5.
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05). Abbreviations are: NaCl,
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP,
adenosine monophosphate; ADO, adenosine; “a” represents significant difference from NaCl; b, significant difference from
NaCl+LPS.
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Figure 11: Acetate prevents LPS-induced increase in AK levels and reduces ADA levels in BV2 microglia.
Cultures were stimulated with 1000 ng/mL LPS for 48 h and adenosine kinase (AK, converts ADO to AMP, Panel A and B) and
adenosine deaminase (ADA, converts ADO to INO, Panel C and D), enzymes were analyzed. Data represent mean ± SD, n ≥ 5.
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05). Abbreviations are: NaCl,
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; AMP, adenosine monophosphate; ADO, adenosine; INO, inosine;
“a” represents significant difference from NaCl; “b” represents significant difference from NaCl+LPS.
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Figure 12: Acetate reduces A1 receptors and prevents LPS-induced increase in A2A receptor levels in BV2 microglia.
Cultures were stimulated with 1000 ng/mL LPS for 48 h and adenosine A1 (A1R; Panel A and B) and A2A (A2AR; Panel C and D)
receptors were analyzed. Data represent mean ± SD, n ≥ 5. Statistical analysis was performed using one way ANOVA followed by
Tukey’s post hoc test (p ≤ 0.05). Abbreviations are: NaCl, sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; “a”
represents significant difference from NaCl; “b” represents significant difference from NaCl+LPS.

Primary astrocyte cultures: As stated above astrocytes play an important role in
modulating purinergic and inflammatory signaling. To determine whether acetate and
LPS alter astrocytic enzymes and receptors involved in adenosine metabolism, primary
astrocytes were treated in the same manner as BV2 microglia. Using western blot
analysis, we found that at 24 h, LPS increased the levels of CD39 protein to 1.7-fold
(Figure 13A and 13B) but had no effect on CD73 protein levels (Figure 13C and 13D).
However, acetate in presence of LPS increased CD73 levels (Figure 13C and 13D) to
2.2-fold above controls and did not alter LPS-induced increase in CD39 levels (Figure
13A and 13B). On the other hand, the levels of enzymes involved in adenosine
metabolism, AK and ADA, were not altered by LPS (Figure 14). But acetate in presence
of LPS increased AK levels (Figure 14A and 14B) to 3-fold above controls while had no
effect on ADA levels (Figure 14C and 14D). At 24 h in primary astrocyte cultures the
adenosine A1 receptors were below the detection level and A2A receptor levels (Figure
15A and 15B) were not altered by LPS or acetate. No significant changes were observed
in any of the adenosine metabolizing enzymes or adenosine receptors at 12 and 48 h of
treatment. Our results in primary astrocytes suggest that the increase in CD73 and AK
enzymes by acetate in presence of LPS may be a compensatory mechanism to replenish
intra-cellular nucleotide levels against LPS-induced increase in ATP metabolism as a
consequence of elevated CD39 levels. Since the changes observed in the enzymes that
form and metabolize adenosine from the extracellular space were opposing and
inconclusive we quantified extracellular adenosine levels in these cultures.
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Figure 13: Acetate increases CD73 but does not alter CD39 levels in primary astrocytes.
Cultures were stimulated with 1000 ng/mL LPS for 24 h and ecto-apyrase (CD39, converts ATP and ADP to AMP, Panel A and B)
and ecto-5’-nucleotidase (CD73, converts AMP to ADO, Panel C and D) enzymes were analyzed. Data represent mean ± SD, n ≥ 5.
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05). Abbreviations are: NaCl,
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP,
adenosine monophosphate; ADO, adenosine; “a” represents significant difference from NaCl; “b” represents significant difference
from NaCl+LPS.
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Figure 14: Acetate increases AK levels but does not alter ADA levels in primary astrocytes.
Cultures were stimulated with 1000 ng/mL LPS for 24 h and adenosine kinase (AK, converts ADO to AMP, Panel A and B) and
adenosine deaminase (ADA, converts ADO to INO, Panel C and D), enzymes were analyzed. Data represent mean ± SD, n ≥ 5.
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05). Abbreviations are: NaCl,
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; AMP, adenosine monophosphate; ADO, adenosine; INO, inosine;
“a” represents significant difference from NaCl; “b” represents significant difference from NaCl+LPS.
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Figure 15: Acetate does not alter adenosine A2A receptor levels in primary astrocytes.
Cultures were stimulated with 1000 ng/mL LPS for 24 h and adenosine A2A (A2AR; Panel A and B) receptors were analyzed. Data
represent mean ± SD, n ≥ 5. Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05).
Abbreviations are: NaCl, sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; “a” represents significant difference from
NaCl; “b” represents significant difference from NaCl+LPS.

Acetate increases astrocyte energy reserves but does not alter extracellular
adenosine levels in primary astrocyte cultures or BV2 microglia
In order to quantify extracellular adenosine levels in astrocyte and BV2 cultures
we developed a highly sensitive HPLC method with fluorescence detection capable of
quantifying pico-mole amounts of adenine nucleotides. To accomplish this, we
optimized the fluorescence derivatization conditions and the HPLC parameters and
achieved baseline separation and accurate quantification of adenine nucleotides.
Nucleotides were converted to their respective 1, N6-etheno derivatives by incubating
with chloroacetaldehyde at pH 4.5 and 60 °C for 60 min. Under these conditions, the loss
of the adenine nucleotides due to hydrolysis was minimized with a derivatization yield of
94.1% for 1, N6-ethenoadenosine as determined by comparison with a pure standard. The
optimal concentration of tetrabutylammonium phosphate (TBAP), the ion-pairing
reagent, required to achieve a reproducible separation of the adenine nucleotides was
found to be 0.8 mM. The limits of detection and quantification for all adenine
nucleotides were approximately 0.08 and 0.16 pmol, respectively. The intra- and interday variability for this method was less than 5.1% and 3.4%, respectively. Separation of
etheno-adenine nucleotides from a standard nucleotide mixture and astrocyte cellular
extracts using this method are shown in Figures 16A and 16B, respectively.
To demonstrate that the newly developed HPLC method can accurately measure
adenine nucleotides, we measured the effect of acetate on intracellular nucleotide levels
in primary astrocyte cultures. Additionally, we also quantified culture phosphagen levels
in order to validate our in vitro model by demonstrating that the alteration in brain energy
metabolites observed in vivo can be replicated in astrocyte cultures. Astrocyte cultures
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Figure 16: Representative HPLC chromatograms for etheno-derivatized adenine
nucleotide analysis from cell cultures.
Panel A shows a standard mixture of adenine nucleotides and , β-methylene adenosine
monophosphate and Panel B shows adenine nucleotides (1:6 dilution) found in a primary
astrocyte culture detected by fluorescence measurement at 280 nm excitation and 410 nm
emission wavelength. Abbreviations are: ADE, adenine; ADO, adenosine; AMP,
adenosine monophosphate; AMPCP, α, β-methylene adenosine diphosphate; ADP,
adenosine diphosphate; ATP, adenosine triphosphate. Solid line represents relative
fluorescence units and the dashed line represents the gradient of buffer B (percent of
total).
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were selected for this analysis since it was known that astrocytes preferentially
metabolize acetate owing to their specialized transport characteristics (Waniewski &
Martin 1998). For this primary astrocyte cultures were treated with 10 mM NaAc for 1,
2, 3, and 4 h where 10 mM NaCl for 2 h served as a control. The control nucleotide
values observed using this method were comparable to the physiological values expected
to be achieved with correctly fixed cultures to prevent degradation of nucleotides
(Balestri et al. 2007, Tang et al. 2010). Using this method we were able to quantify low
AMP levels that are usually undetectable in cultures by conventional methods which
further allowed us to accurately calculate an energy charge ratio of 0.92. With acetate
treatment we found that intracellular ATP levels were reduced at 3 h (Figure 17A), and
AMP levels were reduced at 4 h of treatment (Figure 17C). Cellular ADP levels were
significantly reduced following 1 h of acetate treatment (Figure 17B). Despite changes
in ADP levels starting at 1 h the total nucleotide pool was unaltered at 1 and 2 h of
acetate treatment however a reduction by 27% was observed at 3 and 4 h (Figure 17D).
A significant increase in the calculated energy charge ratio was found at 1 and 2 h of
acetate treatment while at 3 and 4 h the ECR was maintained at control levels (Figure
17E). This demonstrates that at 1 and 2 h of acetate treatment there was an overall
increase in the working cellular energy available to the cell. Further, these results were
supported by an increase in cellular PCr levels to ~3-fold at 1 and 2 h of treatment
compared to controls (Figure 17F). Therefore, until 2 h of acetate treatment our results
corroborate the in vivo findings that acetate supplementation stimulates energy
production. It was interesting to note that at 3 and 4 h acetate treatment reduced the total
68

Figure 17: Acetate increases energy charge ratio and phosphocreatine levels in
primary astrocytes.
Quantification of intracellular ATP (Panel A), ADP (Panel B), AMP (Panel C), total
adenine nucleotides [(ATP+ADP+AMP), Panel D], energy charge ratio
[{ATP+(0.5*ADP)}/(ATP+ADP+AMP), Panel E], and phosphocreatine levels (PCr,
Panel F) in control and acetate-treated primary astrocyte cultures. Data represent mean ±
SD, n= 6, for control, and all acetate treatments. Statistical analysis was performed using
Kruskal-Wallis nonparametric ANOVA followed by Dunn’s post hoc test and the
statistical significance is reported comparing treatment duration to control values (*, p ≤
0.05 ).
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adenine nucleotide pool while the energy charge ratio and PCr levels were maintained at
control levels. Therefore, beyond 2 h it is possible that acetate may stimulate release of
ATP into the extracellular medium or enhance the metabolism of intracellular adenine
nucleotides. Both of which suggest a subsequent increase in adenosine formation, either
due to extracellular metabolism of released ATP or intracellular adenosine formation
followed by release into the extracellular space.
Based on the cellular adenine nucleotide levels and the in vitro changes in levels
of adenosine metabolizing enzymes and receptors describe above, we measured
extracellular levels of adenosine in primary astrocyte and BV2 microglia cells. Using the
same HPLC method, we found that acetate did not alter extracellular adenosine levels in
primary astrocyte (Figure 18A) or BV2 microglia (Figure 18B) over a period of 24 and
48 h, respectively. The lack of changes in extracellular adenosine levels may be due to
rapid adenosine turnover (Noji et al. 2004). A major limitation of these experiments was
studying the effects of acetate on microglia and astrocyte cultures in isolation.
Consequently, mixed glial or organotypic slice cultures where the paracrine signaling
between different cells types is preserved may be a better model to study the effects of
acetate supplementation on purinergic metabolism and signaling.
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Figure 18: Acetate does not alter extracellular adenosine levels in primary astrocyte and BV2 microglia.
Quantification of extracellular adenosine levels in primary astrocyte (Panel A) and BV2 microglia (Panel B) cultures treated with 10
mM NaAc/NaCl in presence or absence of LPS (1000 ng/mL) over a period of 24 and 48 h, respectively. Data represent mean ± SD,
n= 6, for control, and all acetate treatments. Statistical analysis was performed using Kruskal-Wallis nonparametric ANOVA
followed by Dunn’s post hoc test and the statistical significance is reported comparing treatment duration to control values (*, p ≤
0.05).

Acetate treatment increases fatty acid content in BV2 microglia
It is thought that acetyl-CoA derived from acetate can be utilized for lipid
synthesis based on data that demonstrate incorporation of radio-labeled acetate into the
cellular lipid pools (Hellman et al. 1954, Howard et al. 1974). However, it has not been
shown whether supplementing large concentrations of acetate can actually increase
cellular fatty acid, phospholipid, or cholesterol content. Therefore, we treated BV2
cultures with 1, 5, and 10 mM of NaAc in the presence and absence of LPS (6.25 ng/ mL)
for 2 h. We found that acetate alone did not alter the fatty acid content of BV2 microglia.
However, at 2 h in presence of LPS all acetate concentrations (1–10 mM) significantly
increased the total and individual fatty acid content (Table 3–5) in BV2 microglia.
The changes in the fatty acid content from cells treated with 10 mM NaAc in the
presence and absence of LPS for 2 h are shown in Table 3. With 10 mM NaAc+LPS, we
found a 16% increase in stearate (STA, 18:0) compared to the NaCl+LPS group.
However, increases in oleate (OLA, 18:1 n-9, 20%), vaccenate (18:1 n-7, 22%), and
linoleate (LNA, 18:2 n-6, 18%) were observed in the NaAc+LPS group when compared
to the control NaCl group. Other fatty acids including palmitate (PAM, 16:0),
eicosenoate (20:1 n-9), dihomo-γ-linolenate (DGLA, 20:3 n-6), arachidonate (ARA, 20:4
n-6), lignocerate (24:0), adrenate (22:4 n-6), nervonate (24:1 n-9), docosahexaenoate
(DHA, 22:6 n-3) were not altered in any of the treatment groups. Treatment resulted in
an overall 14% increase in the total fatty acid content of BV2 cells comparing the
NaAc+LPS group to NaCl control.
Surprisingly, 5 mM NaAc was able to induce greater percent increases in the fatty
acid content of BV2 microglia as compared to 10 mM NaAc (Table 4). Treatment with
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Table 3: Fatty acid content of BV2 microglia cultures treated with 10 mM acetate in the presence and absence of LPS for 2h.

nmol/mg protein

Fatty Acid
NaCl

NaAc

NaCl+LPS

NaAc+LPS

Palmitate (PAM, 16:0)

40.5 ± 5.7

39.3 ± 6.2

40.8 ± 6.0

45.9 ± 10.6

Stearate (STA, 18:0)

58.7 ± 4.9

60.5 ± 4.8

56.9 ± 5.4

c

104.7 ± 6.2

101.7 ± 3.9

105.5 ± 8.0

Vaccenate (18:1n-7)

27.1 ± 1.8

27.3 ± 1.3

28.9 ± 1.9

a,b,c

33.0 ± 3.1

Linoleate (LNA, 18:2n-6)

24.0 ± 1.1

22.9 ± 0.9

24.8 ± 1.9

a,b,c

28.4 ± 3.4

Eicosenoate (20:1n-9)

6.7 ± 1.1

5.6 ± 0.7

5.7 ± 1.1

7.1 ± 1.4

Dihomo-γ-linolenate (DGLA, 20:3n-6)

4.0 ± 0.9

4.2 ± 0.8

3.6 ± 0.9

4.0 ± 1.3

17.0 ± 1.9

16.3 ± 1.7

17.7 ± 2.1

19.7 ± 3.4

Lignocerate (24:0)

5.8 ± 1.2

5.6 ± 0.9

5.0 ± 1.1

5.3 ± 1.3

Adrenate (22:4n-6)

2.3 ± 0.4

2.1 ± 0.3

2.3 ± 0.4

2.3 ± 0.6

Nervonate (24:1n-9)

5.2 ± 1.1

4.6 ± 0.8

4.2 ± 1.0

4.4 ± 1.3

Docosahexaenoate (DHA, 22:6n-3)

9.7 ± 1.7

9.2 ± 1.5

9.3 ± 1.6

9.7 ± 2.4

Oleate (OLA, 18:1n-9)
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Arachidonate (ARA, 20:4n-6)

a,b,c

66.1 ± 8.7

125.6 ± 13.0

a,b,c
Total fatty acid content
351.7 ± 20.1
342.4 ± 16.3
347.7 ± 27.8
399.1 ± 42.7
a,
Values represent the means ± SD (n = 8) in units of nmol/mg protein; represents significant difference from NaCl group;
b,
represents significant difference from NaAc group; c, represents significant difference from NaCl+LPS group (p ≤ 0.05).

5 mM NaAc+LPS resulted in increases in PAM (99%), STA (29%), OLA (51%), 18:1 n7 (49%), and 18:2 n-6 (54%) compared to the control NaCl group. Other fatty acids 20:1
n-9, DGLA, ARA, 24:0, 22:4 n-6, 24:1 n-9, and DHA were not altered in any of the
treatment groups. An overall increase of 34% in the total fatty acid content of BV2 cells
was observed in the NaAc+LPS group when compared to the control groups.
With 1 mM NaAc+LPS, we found increases in PAM (27%), STA (18%), OLA
(27%), 18:1 n-7 (26%), and 18:2 n-6 (36%) were observed with NaAc+LPS group
compared to the NaCl and NaAc groups (Table 5). Fatty acid 20:1 n-9 showed a 6%
increase from the NaAc group while a 21% and 38% increase in ARA, and DHA was
observed with NaAc+LPS form the NaCl control. Other fatty acid, DGLA, 24:0, 22:4 n6, and 24:1 n-9 were not different in any of the treatment groups. Treatment with 1 mM
NaAc+LPS resulted in an overall increase of 23% in the total fatty acid content in BV2
cells when compared to the NaCl group. Collectively, these data demonstrate that as low
as 1 mM acetate in presence of LPS is capable of increasing individual and the total fatty
acid content in BV2 cells supporting the hypothesis that acetate can stimulate fatty acid
synthesis.

Acetate does not alter total phospholipid content in BV2 microglia
Since we observed a 14-34 % increase in the total fatty acid content with
NaAc+LPS in BV2 microglia, we investigated whether this results in an increase in total
phospholipid content. Phosphorus mass of individual phospholipid classes separated
using TLC was quantified as an index of the phospholipid content with 10 and 5 mM
acetate in the presence and absence of LPS at 2 h. We found that treatment did not alter
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Table 4: Fatty acid content of BV2 microglia cultures treated with 5 mM acetate in the presence and absence of LPS for 2h.

nmol/mg protein

Fatty Acid
NaCl

NaAc

NaCl+LPS

20.7 ± 5.4

26.0 ± 14.9

16.7 ± 4.5

75.9 ± 17.1

86.4 ± 19.0

75.4 ± 14.5

119.0 ± 13.7

135.0 ± 37.8

111.1 ± 14.7

Vaccenate (18:1n-7)

33.3 ± 4.0

37.1 ± 10.5

31.0 ± 3.5

a,b,c

49.5 ± 4.2

Linoleate (LNA, 18:2n-6)

26.8 ± 2.8

31.6 ± 9.0

25.8 ± 2.5

a,b,c

41.1 ± 4.1

20.1 ± 14.8

10.8 ± 5.3

13.4 ± 14.9

12.2 ± 4.5

7.3 ± 4.2

6.4 ± 1.9

6.8 ± 3.1

6.0 ± 0.7

Arachidonate (ARA, 20:4n-6)

26.3 ± 8.4

28.0 ± 6.9

27.4 ± 6.9

33.9 ± 3.5

Lignocerate (24:0)

10.1 ± 6.8

8.9 ± 2.3

10.4 ± 4.9

8.1 ± 1.5

Adrenate (22:4n-6)

5.2 ± 2.4

5.4 ± 1.2

6.0 ± 2.4

5.9 ± 1.0

Nervonate (24:1n-9)

7.4 ± 5.2

6.1 ± 1.7

7.6 ± 3.5

6.3 ± 0.9

17.2 ± 8.6

17.0 ± 4.1

18.5 ± 6.8

18.9 ± 2.2

Palmitate (PAM, 16:0)
Stearate (STA, 18:0)
Oleate (OLA, 18:1n-9)
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Eicosenoate (20:1n-9)
Dihomo-γ-linolenate (DGLA, 20:3n-6)

Docosahexaenoate (DHA, 22:6n-3)

NaAc+LPS
a,b,c
a,c
a,b,c

41.3 ± 6.4

98.1 ± 10.5

179.9 ± 17.5

a,c
Total fatty acid content
406.8 ± 92.8
436.8 ± 114.3
385.5 ± 85.0
545.6 ± 53.6
a,
Values represent the means ± SD (n = 8) in units of nmol/mg protein; represents significant difference from NaCl group;
b,
represents significant difference from NaAc group; c, represents significant difference from NaCl+LPS group (p ≤ 0.05).

Table 5: Fatty acid content of BV2 microglia cultures treated with 1 mM acetate in the presence and absence of LPS for 2h.

nmol/mg protein

Fatty Acid
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NaCl

NaAc

NaCl+LPS

Palmitate (PAM, 16:0)

57.2 ± 5.3

58.8 ± 10.2

61.7 ± 6.7

Stearate (STA, 18:0)

46.8 ± 4.4

48.2 ± 5.6

50.2 ± 1.5

Oleate (OLA, 18:1 n-9)

99.3 ± 8.6

105.1 ± 10.8

111.9 ± 4.3

Vaccenate (18:1 n-7)

26.9 ± 2.1

28.5 ± 2.9

30.4 ± 0.5

a,b

33.9 ± 4.5

Linoleate (LNA, 18:2 n-6)

23.1 ± 1.6

25.3 ± 2.6

28.1 ± 1.0

a,b

31.5 ± 3.9

Eicosenoate (20:1 n-9)

1.5 ± 0.3

1.3 ± 0.2

1.3 ± 0.1

Dihomo-γ-linolenate (DGLA, 20:3 n-6)

1.9 ± 0.4

2.1 ± 0.4

2.0 ± 0.1

13.1 ± 1.5

13.9 ± 1.8

Lignocerate (24:0)

2.4 ± 0.4

2.5 ± 0.4

2.4 ± 0.1

2.6 ± 0.4

Adrenate (22:4 n-6)

1.7 ± 0.6

1.6 ± 0.2

1.7 ± 0.2

2.0 ± 0.4

Nervonate (24:1 n-9)

2.2 ± 0.3

2.4 ± 0.3

2.3 ± 0.2

2.5 ± 0.4

Docosahexaenoate (DHA, 22:6 n-3)

6.3 ± 0.8

7.1 ± 1.2

7.1 ± 0.6

333.5 ± 25.3

343.4 ± 38.8

359.3 ± 13.7

Arachidonate (ARA, 20:4 n-6)

Total fatty acid content

a

a,b

NaAc+LPS
a,b

72.5 ± 12.5

a,b
a,b

55.4 ± 6.6

125.6 ± 14.1

b

1.6 ± 0.2
2.2 ± 0.3

a,b

15.1 ± 0.5

15.9 ± 1.8

a
a,b,c

8.7 ± 2.7

408.7 ± 52.8

Values represent the means ± SD (n = 8) in units of nmol/mg protein; a, represents significant difference from NaCl group;
b,
represents significant difference from NaAc group; c, represents significant difference from NaCl+LPS group (p ≤ 0.05).

the individual phospholipid content in any group of cells treated with either 10 or 5 mM
NaAc+LPS compared to the NaCl group (Table 6 and 7). These results suggest that 2 h
of acetate treatment is not sufficient to increase overall BV2 cell phospholipid content
suggesting the increases in fatty acid content may involve triacylglycerol, or other fatty
acid stores. The impact that treatment had on the fatty acid composition of the individual
phospholipid classes was not determined.

Acetate increases cholesterol levels in BV2 microglia
An alternative pathway for acetate-derived increases in acetyl-CoA may involve
an increase in cholesterol synthesis. To determine if treatment altered cholesterol levels
we quantified the total cholesterol in cells treated with either 5 or 10 mM NaAc in the
presence and absence of LPS for 2 h. A modest but significant increase (11 %) in the
total cholesterol levels was observed in cells treated with 5 mM NaAc (Table 8).
However, no significant change in the total cholesterol levels was observed with 5 mM
NaCL+LPS or 5 mM NaAc+LPS (Table 6) compared to the NaCl group. Cells treated
with 10 mM NaAc in presence or absence of LPS did not alter total cholesterol levels.
These results suggest that acetate, at lower concentrations, can increase total cholesterol
levels similar to that found with total fatty acid content.

Acetate increases histone acetylation in a time- and concentration-dependent
manner
To better understand the time frame of acetate-induced increase in histone acetylation, we
measured the effect that 10 mM acetate had on acetylated histones H3 and H4 at 0.5, 2,
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Table 6: Phospholipid content of BV2 microglia treated with 10 mM acetate in presence or absence of LPS for 2 h.
nmol/mg protein
Phospholipids
NaCl

NaAc

NaCl+LPS

NaAc+LPS

73.5 ± 22.4

85.7 ± 2.7

72.1 ± 14.4

80.0 ± 6.1

139.9 ± 17.0

144.6 ± 11.6

158.1 ± 11.8

166.1 ± 16.4

Sphingomyelin (CerPCho)

49.0 ± 14.5

61.7 ± 12.3

62.5 ± 11.5

87.4 ± 27.1

Phosphatidylinositol (PtdIns)

44.3 ± 18.2

36.3 ± 5.4

38.3 ± 13.1

37.6 ± 16.1

Phosphatidylserine (PtdSer)

32.3 ± 10.3

46.1 ± 19.2

40.6 ± 16.7

42.4 ± 12.8

Ethanolamine glycerophospholipids(EtnGpl)
Choline glycerophospholipids (ChoGpl)
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Values represent the means ± SD (n = 4) in units of nmol/mg protein.

Table 7: Phospholipid content of BV2 microglia treated with 5 mM acetate in presence or absence of LPS for 2 h.
nmol/mg protein
Phospholipid
NaCl

NaAc

NaCl+LPS

NaAc+LPS

58.2 ± 14.8

77.7 ± 15.1

62.5 ± 14.4

65.8 ± 18.4

119.9 ± 16.1

108.3 ± 23.2

96.5 ± 34.7

129.9 ± 22.0

Sphingomyelin (CerPCho)

36.7 ± 3.5

39.2 ± 11.1

35.7 ± 9.6

44.0 ± 13.2

Phosphatidylinositol (PtdIns)

13.7 ± 8.1

22.7 ± 3.5

22.2 ± 9.4

20.1 ± 6.2

Phosphatidylserine (PtdSer)

23.8 ± 5.7

27.4 ± 7.5

26.9 ± 13.5

19.3 ± 2.9

Ethanolamine glycerophospholipid (EtnGpl)
Choline glycerophospholipid (ChoGpl)
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Values represent the means ± SD (n = 4) in units of nmol/mg protein.
Table 8: Cholesterol content of BV2 microglia treated with 5 and 10 mM acetate in presence or absence of LPS for 2 h.
Cholesterol content (µg/mg protein)
Concentration
NaCl

NaAc

NaCl+LPS

NaAc+LPS

10 mM

61.1 ± 6.2

57.1 ± 4.5

60.3 ± 6.1

52.5 ± 5.1

5 mM

66.9 ± 2.6

74.8 ± 3.8

68.4 ± 4.5

73.5 ± 2.4

a

Values represent the means ± SD (n = 4) in units of nmol/mg protein. a, represents significant difference from NaCl group; (p ≤ 0.05).

and 4 h in BV2 microglia. Earlier using these cells we showed that, 12 mM NaAc
increases H3K9 acetylation at 2 and 4 h (Soliman et al. 2012a). However, in this study
we found that 10 mM NaAc was only able to increase H3K9 acetylation at 4 h to 3.4-fold
over control levels (Figure 19A and 19B). On the other hand, acetylation of histone H4
at multiple lysine and/or serine residues was increased to approximately 2-, 2.5- and 5.2fold (Figure 19C and 19D) following 0.5, 2, and 4 h of acetate treatment, respectively.
Histone H4 acetylation at 4 h was significantly higher than 0.5 and 2 h acetate treatment
suggesting that acetate-induced acetylation is progressive and not limited to H3K9. In
order to determine the lowest concentration of acetate required to increase the
acetylation-state of nuclear histones, we measured the concentration effect of acetate
treatment (0.5, 1, 5, and 10 mM) on the acetylation-state of histones H3 and H4. We
found a significant increase in H3K9 acetylation (1.9- and 2.1-fold) in cells treated with 5
and 10 mM NaAc (Figure 20A and 20B). However, the acetylation-state of H3 was not
altered in cells treated with 0.5 or 1 mM NaAc compared to NaCl controls. Similarly, H4
acetylation was increased with 5 and 10 mM NaAc to 2.3- and 3.8-fold (Figure 20C and
20D) over controls while 0.5 and 1 mM NaAc had no effect. Unlike H3K9, the
acetylation-state of H4 with 10 mM NaAc was significantly higher than 5 mM NaAc
suggesting that higher acetate concentrations have the potential to induce acetylation of
multiple acetylation sites on H4. Thus, these data suggest that a minimum concentration
of 5 mM acetate is required to significantly increase histone acetylation and is not limited
to H3K9.
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Figure 19: Acetate increases histone H3 and H4 acetylation-state in a time-dependent manner in BV2 microglia.
Western blot analysis was performed following 0.5, 2, 4 h of acetate (10 mM) treatment to determine temporal changes in acetylated
H3K9 (Panel A), and acetylated H4S1/K5/K8/K12 (Panel C), normalized to total H3 (Panel A) and total H4 (Panel C), respectively.
Panel B and D show quantification of the changes in the acetylation-state of histone H3 and H4, respectively. Data represent mean ±
SD (n=3, p ≤ 0.05) where a, b, and c represent statistically significant difference from 0.5, 2 and 4 h sodium chloride (NaCl) while α,
and β represent statistically significant difference from 0.5 and 2 h sodium acetate (NaAc) treatments.
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Figure 20: Acetate increases histone H3 and H4 acetylation-state in a concentration-dependent manner in BV2 microglia.
Western blot analysis was performed with 0.5, 1, 5, and 10 mM acetate (4 h) to determine concentration-dependent changes in the
acetylated H3K9 (Panel A), and acetylated H4S1/K5/K8/K12 (Panel C), normalized to total H3 (Panel A) and total H4 (Panel C),
respectively. Panel B and D show quantification of the changes in the acetylation-state of histone H3 and H4, respectively. Data
represent mean ± SD (n=3, p ≤ 0.05) where a, b, c, and d represent statistically significant difference from 0.5, 1, 5 and 10 mM sodium
chloride (NaCl) while α, β, and γ represent statistically significant difference from 0.5, 1, and 5mM sodium acetate (NaAc) treatments.

CHAPTER IV
DISCUSSION
Acetate supplementation increases plasma acetate by 100-fold (19.3 ± 4.72 mM)
in rats (Reisenauer et al. 2011) and brain acetate by 17-fold (8.5 µmol/g brain ~10.6 mM)
in mice (Mathew et al. 2005) treated with a single oral dose of 6 or 5.8 g/kg body weight
glyceryl triacetate (GTA), respectively. Acetate crosses the blood brain barrier
(Deelchand et al. 2009) and is preferentially taken up by astrocytes through facilitated
transport via monocarboxylate transporters (MCT) (Waniewski & Martin 1998). Acetate
is further activated to acetyl-CoA by either cytosolic or mitochondrial acetyl-CoA
synthetase enzymes (Hallows et al. 2006). In support of this mechanism, acetate
supplementation increases brain acetyl-CoA levels by 2.2-fold (5.7 ± 1.9 µg/g tissue ~8.7
± 2.9 µM) within 30 min and remains elevated out to 4 h following treatment (Reisenauer
et al. 2011). Acetyl-CoA is a substrate for various pathways including protein
acetylation, the TCA cycle, and lipid synthesis. Regarding protein acetylation, single and
multiple oral doses of GTA increase acetylation of histone and non-histone proteins that
in turn alter inflammatory gene expression (Soliman & Rosenberger 2011, Soliman et al.
2012b). However, the influence that acetate supplementation has on brain purine and
lipid content has not been tested. Therefore, we sought to measure the effect that single
and multiple oral doses of GTA had on brain nucleotides, phosphagens, and
mitochondrial biogenesis in normal rats. We found that 4 h after a single oral GTA
administration, brain PCr levels were increased (Bhatt et al. 2013) significantly compared
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to controls (Figure 4), consistent with the increase in brain acetyl-CoA levels
(Reisenauer et al. 2011). However, changes in brain ATP (Figure 2A), ADP, GTP, or
NAD levels (listed in results) remain unaltered. Furthermore, daily GTA administration
for a period of 28 days in normal rats (Figure 6) or rats subjected to LPS-induced
neuroinflammation (listed in results) did not alter PCr or brain nucleotide levels.
The metabolic half-life of ATP is only a few milliseconds and is controlled by a
balance of cellular energy supply and demand (Erecinska & Silver 1989). In these
experiments, rats were not challenged by noxious stimuli nor was there an increase in the
energy demand due to disease pathology. Thus, we speculate that the energy generated
as a result of mitochondrial acetyl-CoA metabolism would be stored in the form of PCr.
ATP and other adenylate metabolites are key regulators of metabolic pathways that
maintain cellular homeostasis and thus their levels are tightly regulated (Wallimann et al.
1992). Phosphocreatine, on the other hand, is metabolically inert with regard to
biochemical regulation and serves as a reservoir of energy (Wallimann et al. 1992).
During increased metabolic demand or diseased states, the brain can utilize PCr to
maintain ATP levels (Meyer et al. 1984). Following injury, a decrease in PCr levels
precedes ATP loss (Lowry et al. 1964, Norberg et al. 1975) and thus it is important to
monitor and maintain both ATP and PCr levels. In this regard, acetate supplementation
partly restores brain ATP levels in a rat model of traumatic brain injury (Arun et al.
2010a), however PCr levels were not measured in this study and the ATP restoration may
have been secondary to the neuroprotective effects of GTA. Our results substantiate
these findings by demonstrating that acetate supplementation can directly influence basal
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PCr levels. Since labeled-acetate is known to enter the glial glutamine pool it may be
argued that the observed changes in PCr levels, in this study, predominantly reflect
changes occurring in astrocytes. However, mitochondrial creatine kinase, the enzyme
responsible for PCr formation, is selectively expressed in neurons but not in astrocytes
whereas the cytosolic form of creatine kinase is expressed by both the cell types
(Tachikawa et al. 2004). Thus, analysis of changes in PCr levels in individual cell types
in vitro is required to determine which cell type contributes towards an increase in PCr
levels. Further, during long-term acetate supplementation the brain may adapt to
constantly elevated acetyl-CoA levels by diverting its utilization to other pathways like
glycogen synthesis, lipid synthesis, purine metabolism or protein acetylation. As
mentioned earlier, we have shown that GTA induces histone acetylation in a rat model of
neuroinflammation and is associated with decrease in interleukin-1β expression (Soliman
et al. 2012b). Therefore, we measured the effect of GTA and/or acetate on glycogen
levels, purine metabolism, and lipid content in in vivo and in vitro models as described
below.
At 4 h of single-dose acetate supplementation there was a modest but significant
reduction in brain AMP levels (Figure 2B) which coincide with the increase in PCr
levels. The creatine-phosphate shuttle is responsible for the transfer of high energy
phosphate between PCr/Cr and ATP/ADP, however AMP is not involved in this transfer
(Meyer et al. 1984). Since we did not observe significant changes in the ATP, ADP or Cr
levels, there appears to be a discrepancy between increases in PCr levels and its
biochemical relationship to other components of the creatine kinase system. This may
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partially be explained by increase in free [Mg2+] as a result of ATP hydrolysis induced by
microwave irradiation (Srivastava et al. 2012) and subsequent changes in the equilibrium
constant of the creatine kinase reaction (Lawson & Veech 1979). Nonetheless, given the
increase in PCr and the tight control over cellular ATP and ADP levels under normal
conditions the observed reduction in AMP suggests an overall increase in the cellular
energy supply. Alternatively, increased acetyl-CoA may result in a situation where AMP
can be metabolized to adenosine. In the brain, adenosine levels are in the picomolar
range while AMP levels are in the nanomolar range (Delaney & Geiger 1996), which
suggests that a small change in AMP can lead to a dramatic increase in brain adenosine.
In support of this, it has been demonstrated that acetate uptake by neurons induces
intracellular acidosis resulting in stimulation of the sodium hydrogen exchanger and the
sodium potassium ATPase which consume ATP and result in adenosine release (Zamzow
et al. 2006). Adenosine is known for its anti-inflammatory and neuroprotective
properties (Cunha 2005, Ribeiro 2005), and acetate supplementation attenuates neuroglia
activation and prevents loss of choline-acetyl transferase immuno-reactivity in rats
subjected to neuroinflammation (Reisenauer et al. 2011). Consequently, this suggests
that increasing mitochondrial energy reserves and possibly adenosine levels may
contribute to the neuroprotective and anti-inflammatory effects of acetate
supplementation. However, since acetyl-CoA is a ubiquitous substrate for various
biochemical pathways there can be multiple mechanisms underlying the beneficial effects
of acetate supplementation. Although increase in energy is beneficial, a direct link to the
anti-inflammatory effect of acetate supplementation remains elusive. Since in the brain,
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ATP and adenosine modulate inflammation through purinergic receptor signaling (Di
Virgilio et al. 2009b) altering purine levels and their receptor expression has the potential
of disrupting the neuroinflammatory response.
An alternative energy reserve available to the brain is glycogen, which is
primarily localized in astrocytes as cytoplasmic granules. Although brain glycogen is
primarily localized in astrocytes the enzyme glycogen synthase involved in glycogen
synthesis is expressed in neurons as well as astrocytes. Alternatively, glycogen
phosphorylase, the enzyme responsible for glycogen breakdown is primarily astrocytic
(Brown 2004). Since acetate is preferentially utilized by astrocytes it is possible that in
our experiments acetate utilization may divert glucose towards glycogen synthesis in
astrocytes or rather spare glucose for neuronal utilization. During insulin-induced
hypoglycemic conditions, brain glycogen levels fall in areas with high metabolic rate,
suggesting that brain glycogen is used to support brain energetics (Brown 2004). Thus,
we measured brain glycogen levels in animals treated with GTA for 4 h, and 28 days.
Interestingly, single-dose and long-term acetate supplementation did not alter brain
glycogen levels. Estimated glycogen turnover rates are between 5-10 h (Choi & Gruetter
2003, Morgenthaler et al. 2009) which explains the absence of changes in glycogen
levels with 4 h of GTA treatment. Further, a 28 day treatment regimen is sufficient to
observe any significant changes in glycogen synthesis. However, absence of changes in
glycogen with long-term treatment suggests that GTA does not affect brain glycogen
synthesis or during this long period the reserve energy is utilized for other biochemical
pathways. As stated above, same can be true with acetate utilization, owing to its
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ubiquitous nature acetyl-CoA may be channeled into other metabolic pathways like lipid
synthesis or protein acetylation. In this regard, acetate supplementation increases brain
histone acetylation in vivo and in vitro in astrocyte and microglial cultures (Soliman et al.
2013a, Soliman et al. 2012a, Soliman & Rosenberger 2011, Soliman et al. 2012b).
Nonetheless, acetate utilization by astrocytes may reduce glial glucose utilization and
increase neuronal glucose availability.
Alternatively, it is possible that under significantly high acetate levels achieved
with acetate supplementation, neurons may also utilize acetate for energy production.
The molecular basis for astrocyte-specific uptake of acetate has only been tested by two
studies with conflicting results. Rat cortical astrocytes generate labeled-CO2 18 times
faster than cortical synaptosomes suggesting that acetate is preferentially utilized by
astrocytes compared to neurons (Waniewski & Martin 1998). However, it is possible that
alternative TCA cycle intermediates are synthesized in astrocytes verses neurons or that
acetate-derived acetyl-CoA is channeled into different biochemical pathways by the two
cell types. Waniewski and Martin attribute the difference in labeled-CO2 production to
the selective uptake of acetate by astrocytes via monocarboxylic acid-like transporters
(Waniewski & Martin 1998). However, neurons are known to express monocarboxylic
acid transporters (Pierre & Pellerin 2005) and the activity of acetyl-CoA synthetase, the
enzyme responsible for acetate utilization, is higher in synaptosomes (Waniewski &
Martin 1998) suggesting that neurons can also transport and utilize acetate. This is
substantiated by studies demonstrating that neuronal MCT2 transports acetate with
affinities comparable to that of astrocytic MCT1 (Km ~1.6–2.5 mM) (Rae et al. 2012),
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however acetate transport may be limited in presence of lactate (Moschen et al. 2012).
On the other hand, Brand et al. demonstrated that acetate can be metabolized by both the
cell types and that in neurons acetate-derived labeled-carbon is recovered as glutamate
and aspartate while in astrocytes as glutamine (Brand et al. 1997). The major difference
between the experimental paradigms of these two studies is the concentration of labeledacetate used, 0.2 and 5 mM, respectively. Moreover, most in vivo glial metabolism
studies utilize labeled-acetate at either physiological (~0.2 mM) or much lower levels
which are well below normal glucose levels where acetate utilization is primarily
astrocytic. Brain acetate levels achieved with GTA administration are approximately 10
mM (8.5 µmol/g brain) (Mathew et al. 2005), twice the normal glucose levels (5 mM).
Thus, at such high acetate concentrations the excess acetate may be utilized by neurons,
especially considering that synaptosomes have significantly higher acetyl-CoA synthetase
activity compared to astrocytes (Waniewski & Martin 1998). At this point it cannot be
attributed whether the observed in vivo effects of acetate supplementation are
predominantly astrocytic or neuronal. However, future in vitro studies measuring the
effect of different acetate concentrations on individual cell types could allow us to make
the necessary distinction.
Because acetate supplementation and ketogenic diet share a common metabolic
intermediate, acetyl-CoA, it is important to understand the influence that acetate
supplementation has on mitochondrial biogenesis. Ketogenic diet being a high-fat lowcarbohydrate diet enhances hepatic β-oxidation of free fatty acids and increases
circulating levels of β-hydroxy butyrate (BHB), the predominant ketone body, from 0.2
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mM to 3.9 mM in mouse plasma (Yudkoff et al. 2005). In brain, the uptake of ketones
across the BBB is mediated by monocarboxylic acid transporters where they are taken up
by both neurons and astrocytes (Cremer 1971, Melo et al. 2006). Once inside the cell,
BHB bypasses the glycolytic steps, enters the mitochondria, and is converted into
acetoacetate, acetoacetyl-CoA, and finally acetyl-CoA based on NAD+ availability
(White & Venkatesh 2011). Ketone bodies formed as a result of 4 weeks on a ketogenic
regimen increase the number of mitochondria in hippocampal neurons (Bough et al.
2006). However, we found that a 28 day treatment with GTA did not alter hippocampal
CA3 neuronal mitochondrial number (Figure 5). Post-synaptic inter-neurons in the CA3
region receive axonal input from entorhinal cortex and dentate gyrus and relay
information to the CA1 cell bodies. Since acetate is preferentially utilized by glia
(Waniewski & Martin 1998), absence of changes in neuronal mitochondrial number does
not exclude changes in astrocytic mitochondria. Thus, to detect global changes in
mitochondrial mass, we quantified cardiolipin levels and cardiolipin fatty acid content in
whole brain. However, we did not find significant changes in whole brain mitochondrial
mass or cardiolipin fatty acid composition (Table 1). This suggests that acetate
supplementation does not significantly alter the synthesis of new mitochondria in whole
brain although changes in their size and distribution in specific brain compartments
cannot be ruled out. We primarily focused on comparing the known effects of ketogenic
diet on mitochondrial biogenesis in hippocampal neurons with that of acetate
supplementation. Nonetheless, considering the preferentially utilization of acetate by
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astrocytes, investigation of how acetate supplementation affects astrocytic mitochondrial
biogenesis is required.
One of the proposed mechanisms by which the ketogenic diet increases
mitochondrial biogenesis is activation and increased expression of the transcription
factor, peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α)
(Wallace et al. 2010). PGC-1α is considered as the master regulator of mitochondrial
biogenesis and is regulated by reversible acetylation. Sirtuin 1 (Sirt1) is a NAD+dependent cytosolic protein deacetylase that activates PGC-1α by removing the acetyl
group (Rodgers et al. 2005). Since ketone bodies are utilized exclusively inside the
mitochondria they spare cytosolic NAD+ which is normally consumed during glycolytic
metabolism (Wallace et al. 2010). This activates Sirt1 resulting in deacetylation of PGC1α and induction of mitochondrial biogenesis. Further, limited carbohydrate availability
with ketogenic diet reduces insulin levels and enhances glucagon secretion both of which
through independent signaling pathways up-regulate PGC-1α expression and thus induce
mitochondrial biogenesis (Wallace et al. 2010). Acetate supplementation, on the other
hand, does not reduce carbohydrate availability, elevates cytoplasmic and mitochondrial
acetyl-CoA levels, and as suggested earlier may increase neuronal glucose availability.
Thus, cytosolic acetyl-CoA through protein acetylation may maintain the normal
acetylation-state of PGC-1α and prevent induction of mitochondrial biogenesis. It can be
argued that like ketone bodies, acetate may also spare cytosolic NAD+ and activate Sirt1
to induce mitochondrial biogenesis. However, another effect of Sirt1 activation is that it
activates acetyl-CoA synthatase by NAD+-dependent deacetylation (Wilhelm &
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Hirrlinger 2012). Thus, this utilized NAD+ and elevates acetyl-CoA levels which can be
used to maintain normal acetylation-state of PGC-1α and mitochondrial biogenesis. The
exact mechanisms that regulate acetate utilization in different cellular compartments are
still unclear however this may partially explain the differential effects of ketogenic diet
and acetate supplementation on mitochondrial biogenesis. Therefore, while the two
treatments share similarity at increasing acetyl-CoA levels our results suggests that
acetate supplementation unlike the ketogenic diet does not result in mitochondrial
biogenesis.
The accurate determination of high-energy phosphates requires rapid brain
fixation to instantaneously stop their metabolism. Head-focused microwave irradiation is
a quick technique to rapidly inactivate enzymes while preserving the structural integrity
of the brain. For in vivo nucleotide and phosphagen analysis we used 6 kW output power
with a 2 sec exposure, as described (Delaney & Geiger 1996). Consequently, the
nucleotide content obtained in this study closely resembles the reported values obtained
using comparable microwave conditions (Delaney & Geiger 1996, Gupta & Dettbarn
2003). Nonetheless, brain ATP levels obtained by microwave fixation are lower, and
ADP and AMP levels are subsequently higher than those obtained by freeze blowing or
in-situ funnel freezing techniques (Ponten et al. 1973, Veech et al. 1973). In addition to
differential inactivation of nucleotide metabolizing enzymes (Nelson 1973), microwave
irradiation can directly break the high energy phosphate bond in ATP and result in an
approximate 30% ATP loss compared to the freeze blowing method (Srivastava et al.
2012). The phosphate bond in PCr is however stable to thermal degradation and creatine
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kinase, the enzyme that converts PCr to creatine, is efficiently inactivated by microwave
irradiation (Nelson 1973) resulting in PCr values similar to those obtained with freeze
blowing (Srivastava et al. 2012).
In order to integrate GTA-induced changes in energy levels with the potential to
alter purinergic metabolism, we investigated the effect that acetate supplementation had
on purinergic enzymes and receptors in a rat model of neuroinflammation. Our results
show that acetate supplementation was able to modulate brain ecto-5’-nucleotidase
(CD73) and adenosine kinase (AK) as well as the levels of the adenosine A2A receptor,
which may describe a mechanism by which acetate exerts its observed anti-inflammatory
and potentially neuroprotective effects. The premise that bioenergetic stimulation can
influence neuroinflammation has been demonstrated in various animal models of
Alzheimer’s disease and Parkinson’s disease, as well as in Parkinson’s disease patients
(Beal 2004). Acetyl-L-carnitine, like acetate, bolsters mitochondrial metabolism in
astrocytes and is neuroprotective in a rat model of traumatic brain injury (Scafidi et al.
2010). Similarly, the closest metabolic correlate of acetate supplementation, the
ketogenic diet, also modulates brain mitochondrial metabolism, and is neuroprotective
(Bough et al. 2006, Ruskin & Masino 2012) through a mechanism involving adenosine
(Masino et al. 2010). With 14 and 28 day prophylactic acetate supplementation we found
that GTA was able to prevent LPS-induced reduction in CD73 levels in addition to
increasing CD73 activity (Figures 7 and 8). This suggests that GTA can elevate brain
adenine nucleotide metabolism to potentially increase extracellular levels of adenosine.
Furthermore, interventional acetate supplementation increased CD73 levels however
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lower CD73 activity was observed with GTA as compared to the LPS group (Figure 9).
Cortical stab wound and focal cerebral ischemia models of brain injury have
demonstrated a biphasic alteration in CD73 expression and activity, where an initial
decrease is followed by a distinct increase in expression and activity of CD73 during the
post-injury period (Bjelobaba et al. 2011, Braun et al. 1997, Nedeljkovic et al. 2006).
Thus, this suggests that the interventional GTA may require a longer treatment period to
increase CD73 activity.
Another key enzyme that regulates extracellular levels of adenosine is adenosine
kinase (AK). Although intracellular, the low Km of AK for adenosine (1.5–2.4 µM)
(Arch & Newsholme 1978) combined with the bidirectional and equilibrative nature of
adenosine transporters, allows AK to control adenosine uptake. We found that 28 days of
LPS-infusion increased AK levels as seen during traumatic brain injury and epilepsy
(Aronica et al. 2011, Boison 2006) (Figure 8). This increase was prevented by the longterm prophylactic treatment which suggests that GTA in the presence of LPS is able to
enhance extracellular adenosine availability by preventing the increase in its uptake and
conversion to AMP. However, this may lead to a scenario where, elevated adenosine
levels become more susceptible to adenosine deaminase (ADA) mediated degradation to
inosine, since ADA is a high capacity high Km (34 µM) enzyme (Arch & Newsholme
1978, Fredholm 2007). As these alterations may be cell-type specific, an in depth in vitro
analysis of all purinergic enzymes is required to get a comprehensive view of how acetate
alters adenosine metabolism.
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Extracellular adenosine is an endogenous agonist for four different G proteincoupled receptors (A1, A2A, A2B, and A3), of which the A1 and A2A receptors have the
greatest relevance in the central nervous system (Fredholm et al. 2001, Klotz 2000). The
A1 receptor signal cascade generally suppresses neuronal activity, inhibits synaptic
transmission, and reduces the activation and response of microglia (Fredholm et al.
2005b, Haselkorn et al. 2010). Adenosine A2A receptors are responsible for mediating
LPS-induced neuroinflammation and neuronal dysfunction (Rebola et al. 2011).
Antagonists of the A2A receptors have been shown to be anti-inflammatory in a number
of CNS disorders (Brothers et al. 2010, Fredholm et al. 2005b, Rebola et al. 2011, Wei et
al. 2011). In specific regards to our model, it was found that the A2A receptor inhibitor
caffeine attenuates LPS-induced neuroinflammation (Brothers et al. 2010). We found
that at 14 days, LPS-induced neuroinflammation caused a significant increase in A2A
receptor levels compared to controls (Figure 7), in line with our previous findings that
show an increase in IL-1β expression (Soliman et al. 2012b), which is known to increase
A2A receptor levels (Trincavelli et al. 2002). Fourteen day prophylactic acetate
supplementation prevented this LPS-induced increase (Figure 7) in A2A receptors, which
is in agreement with results demonstrating that GTA attenuates LPS-induced proinflammatory release (Soliman et al. 2012b). Since blockade of A2A receptors prevents
IL-1β induced exacerbation of neuronal toxicity (Simoes et al. 2012), acetate
supplementation has a combined effect of reducing IL-1β levels (Soliman et al. 2012b)
and A2A receptors that could offer robust neuroprotection by attenuating
neuroinflammation. However, interventional acetate supplementation further increased
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A2A receptor levels (Figure 9). The reason for this difference is not clear yet but a
bidirectional effect of A2A receptors in neuroinflammation has been described in the
literature (Dai & Zhou 2011). It is possible that interventional acetate supplementation
started after significant morphological changes in neuroglia have already occurred may
not be sufficient to counteract the LPS-induced elevation in A2A receptor levels.
However, the ability of the A2A receptors to control neuroinflammation is dependent on
local glutamate levels and is critical in determining whether their stimulation results in
anti-inflammatory or pro-inflammatory effects (Dai & Zhou 2011). Distinct pathological
stages after injury respond to different A2A receptor modulators. For example, during
early spinal cord injury A2A receptor agonists offer neuroprotection while A2A receptor
knockout was neuroprotective only during later injury stages (Li et al. 2006). Thus, an
alternative reasoning may be that the increase in A2A receptors observed with
interventional GTA may be beneficial by enhancing the effects of endogenous adenosine
during this 14 day treatment and contributes towards the anti-inflammatory effect of
acetate supplementation. However, to make this determination a thorough investigation
of temporal changes in inflammatory markers, A2A receptors, and local glutamate levels
with LPS and GTA is required. A limitation of the interventional study was the lack of
the aCSF control group which would have allowed us to determine whether the increase
in A2A receptors was indeed an elevation from control levels. Thus, future studies that
examine the effect of interventional GTA strategy for longer treatment duration with
proper controls are necessary. Regardless, prophylactic acetate supplementation does
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prevent the LPS-induced increase in A2A receptor levels, which may help to explain the
mechanism by which GTA confers its anti-inflammatory effects.
As stated before, acetate supplementation increases histone acetylation (Soliman
& Rosenberger 2011) and reverses LPS-induced histone H3 at lysine 9 (H3K9)
hypoacetylation in a model of neuroinflammation (Soliman et al. 2012b). Histone
hyperacetylation alters gene expression and also induces anti-inflammatory effects
(Strahl & Allis 2000, Adcock 2007). Therefore, it is reasonable to speculate that acetate
induced histone acetylation may be a potential underlying mechanism involved in the
modulation of adenosine metabolizing enzymes CD73 and AK as well as the levels of the
adenosine A2A receptors, especially at the level of gene transcription. Future studies will
determine the link between acetate-induced histone acetylation changes and alteration in
the levels of these proteins. Using specific histone acetyltransferase inhibitors to block
the effect of acetate on histone acetylation will allow us to determine its role in altering
levels of adenosine metabolizing enzymes and receptors. Further, by studying if
acetylated H3K9 is associated with the gene promoters of adenosine metabolizing
enzyme and receptor will determine if acetate-induced alteration in their expression is
controlled by, acetylated H3K9.
To better characterize the in vivo changes in purinergic enzymes and receptors
considering the involvement of multiple cell types in purinergic signaling and the
neuroinflammatory response, we investigated the effect of acetate on purinergic enzymes
and receptors in isolated BV2 microglia and primary astrocyte cultures. In addition to
CD73 and AK enzymes, and A2A receptors, that were measured in vivo we also quantified
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levels of ecto-apyrase (CD39), ADA, and adenosine A1 receptors. Cultures were treated
with sodium acetate (NaAc, 10mM) and sodium chloride (NaCl, 10 mM), as osmolarity
control, both in the presence and absence of LPS (1000 ng/mL) to induce inflammation.
We found that acetate was able to prevent or reduce LPS-induced changes in most of the
adenosine metabolizing enzymes and receptors measured in BV2 microglia but not in
primary astrocytes. However, there were some similarities and dissimilarities between
the in vivo and in vitro results that are discussed below.
In contrast to the in vivo neuroinflammation model LPS increased CD73 levels in
BV2 microglia indicating greater AMP breakdown into adenosine which was prevented
by acetate in presence of LPS (Figure 10C and 10D). Further, the CD39 levels in BV2
microglia were not affected by LPS but acetate in presence of LPS reduced CD39 levels
to below control levels suggesting reduced ATP and ADP breakdown to AMP (Figure
10A and 10B). On the other hand, we found that LPS increased AK levels similar to the
in vivo results which were prevented by acetate treatment in presence of LPS (Figure
11A and 11B). This reduction in AK-mediated adenosine metabolism was further
strengthened by a concomitant reduction in LPS-induced elevation of ADA levels by
acetate to below control levels causing marked reduction in adenosine degradation
(Figure 11C and 11D). It is interesting to note that the effects of acetate on the enzymes
that form adenosine (CD39 and CD73) and the ones that metabolize it (AK and ADA) are
opposing to one another. However, the Km values of AK (1.5–2.4 µM) and ADA (34
µM) are at least 100- and 10-fold lower than CD39 (600 µM) and CD73 (245 µM),
respectively (Arch & Newsholme 1978). Thus, AK and ADA are rate-limiting at either
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normal (20–50 nM) or pathological (100–1000 nM) levels of adenosine making their
contribution to the regulation of extracellular adenosine levels more significant. In other
words, extracellular adenosine levels will be more sensitive to a 2-fold reduction in AK
and ADA levels than a comparable reduction in CD39 and CD73 levels. This may
partially support the premise that acetate can increase extracellular adenosine availability.
However, this is only theoretical and changes in enzyme activities and direct extracellular
adenosine measurements are required to draw definitive conclusions. LPS-stimulation in
BV2 microglia increased A2A receptors which are in agreement with studies
demonstrating that LPS induces A2A receptor mRNA (Orr et al. 2009) and protein levels
(Gomes et al. 2013) in in vitro microglial cultures. Acetate treatment further prevented
LPS-induced elevation of A2A receptors (Figure 12C and 12D) similar to the in vivo
results suggesting ramification and reduction in the inflammatory response (Orr et al.
2009). However, A1 receptor levels were also reduced to below control levels with
acetate treatment in presence of LPS (Figure 12A and 12B). This decrease in A1
receptors may be reflective of an overall decrease in the inflammatory response in
microglia.
In primary astrocytes, we found that acetate in the presence of LPS increased
CD73 levels indicative of greater adenosine formation similar to the in vivo
neuroinflammation model (Figure 13C and 13D). However, CD39 levels were only
increased by LPS and not altered by acetate in presence of LPS (Figure 13A and 13B).
In contrast to the in vivo results, while LPS did not affect AK levels, acetate increased
AK levels in presence of LPS (Figure 14A and 14B). Perhaps, this increase in
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adenosine metabolism may be a compensatory mechanism to counteract the increase in
CD39 and CD73 levels in order to replenish cellular adenine nucleotides. Further,
neither LPS nor acetate were able to alter ADA (Figures 14C and 14D) and A2A receptor
levels (Figures 15A and 15B) in astrocytes while the A1 receptors were below the level
of detection. Although not definitive the effect of acetate in primary astrocytes suggests
an overall increase in adenosine metabolism. Combining the results obtained in primary
astrocytes with those obtained in BV2 microglia raise multiple discrepancies as to how
these changes relate to the in vivo results and whether they actually result in elevated
adenosine levels. To test this, we developed a HPLC based method with fluorescence
detection to detect low adenine nucleotide and adenosine levels in cell cultures.
The newly developed HPLC method (Figure 16) was used to accurately quantify
intracellular adenine nucleotide levels and replicate the in vivo purine metabolism model
in primary astrocyte cultures (Figure 17). These measurements showed that acetate
increased cellular energy charge ratio and PCr levels at 2 h of treatment supporting the
bioenergetic hypothesis. Additionally, it also suggests that beyond 3 h acetate treatment
stimulates release of intracellular ATP which is in line with the purinergic metabolism
hypothesis. However, when the same method was used to quantify extracellular
adenosine levels in primary astrocytes and BV2 microglia no significant changes were
observed (Figure 18). Thus, the study of purinergic metabolism in isolated BV2
microglia and astrocytes appears to be much more complex than initially conceived. It is
possible that purinergic signaling is dependent upon paracrine communication between
different cell types including microglia, astrocyte, and neurons. Thus, a major limitation
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of these experiments was studying the effects of acetate on microglia and astrocyte
cultures in isolation. In this regard, conflicting adenosine receptor functions can be
observed in vitro, since it is difficult to maintain a homogenous glial population with
defined activation state (Fredholm 2007). Therefore, diverse co-culture paradigms
including mixed glial cultures co-cultured in presence and absence of neurons, or
organotypic slice cultures may serve as better model systems to characterize the effects of
acetate on purinergic signaling. Further, pretreatment of cultures with adenosine
transport and degradation inhibitors can greatly enhance the half-life of extracellular
adenosine. However, the current results suggest that acetate may not alter the
endogenous levels of adenosine but with the altered purinergic machinery may be able to
respond to the release of endogenous nucleotides in a way that promotes antiinflammation and neuroprotection.
In order to demonstrate whether acetate-induced acetyl-CoA can stimulate lipid
synthesis, we investigated the effect of acetate in the presence and absence of LPS on
fatty acid, phospholipid, and cholesterol content in BV2 microglia. Not much is known
about the fatty acid and phospholipid content of BV2 microglia. However, a few studies
have reported that stimulation of BV2 cells with saturated fatty acids results in a proinflammatory response via Toll-like 4 receptor/NF-κB signaling pathways (Gupta et al.
2012, Tracy et al. 2013, Wang et al. 2012). As a proof-of-principle, we found that
acetate increased the fatty acid (Table 3–5) and cholesterol (Table 8) content of BV2
cells without altering individual phospholipid levels (Table 6 and 7). These data support
the hypothesis that acetate can stimulate fatty acid synthesis but future studies are
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required to determine if the changes in fatty acid content are in fact due to an increase in
de novo synthesis or reduction in β-oxidation. Further, investigating the fatty acid
composition of various phospholipid classes will provide more information as to how the
fatty acids are being distributed inside the cell and understand the significance this has on
membrane order and lipid signaling.
Brain acetate availability is reduced in the white matter of multiple sclerosis
patients (Li et al. 2013) and acetate supplementation increases myelin galactocerebrocide
levels in a rat model of Canavan disease (Arun et al. 2010b). In this regard, results of
this study suggest that acetate can be used to not only directly replenish brain acetate
levels but can also be utilized for lipid synthesis. Acetate in presence of LPS at 2 h
elevates cellular fatty acid content in a concentration-dependent manner with the greatest
increase found at 5 mM followed by 1 and 10 mM NaAc+LPS. The exact reason for a
lower increase in fatty acid content with 10 mM NaAc+LPS is not yet clear. However, it
is known that de novo fatty acid synthesis and histone acetylation compete for the same
acetyl-CoA pools (Galdieri & Vancura 2012). Therefore, it is possible that higher acetate
concentrations are utilized for other biochemical pathways as well as for histone
acetylation.
Alternatively, fatty acids synthesized as a result of higher acetate concentration
may induce a negative feedback inhibition on lipid synthesis (Tong 2005). The activity
of the rate limiting enzyme, acetyl-CoA carboxylase (ACC), in lipid synthesis is
controlled by phosphorylation. Phosphorylation deactivates ACC and reduces malonylCoA formation, the substrate for lipid synthesis. The enzymes AMP kinase
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phosphorylates ACC, which in turn is activated by AMP and long chain acyl-CoA levels
(Tong 2005). Both of which are formed as a result of elevated lipid synthesis and thus it
is possible that they exert a phosphorylation mediated inhibition of ACC activity and
lipid synthesis at higher acetate concentration. Nonetheless, 1 and 5 mM acetate in
presence of LPS increased the total fatty acid content by 23 and 34%, respectively. It
would be interesting to know whether longer treatment intervals with lower acetate doses
can achieve greater elevation in the fatty acid content and distribution in vivo.
Significant increases in the saturated fatty acids, PAM and STA, suggest an
increase in the de novo fatty acid synthesis which can be further metabolized to other
unsaturated fatty acids. The lack of an increase in fatty acids having a acyl-chain length
greater than 20 carbon atoms suggest that the observed changes may not a be a result of
an increase in uptake of fatty acids from the culture medium or alternatively may reflect
low levels of these fatty acid in the medium. On the other hand, the increase in LNA, an
essential fatty acid, must represent an increase in uptake of exogenous LNA. This uptake
may be enhanced in presence of LPS since it has been shown that in vivo LPS-infusion
increases the brain concentrations of LNA and ARA (Rosenberger et al. 2004). It is
interesting to note that increase in the total and individual fatty acid contents were only
observed in the NaAc+LPS group but not in the NaAc group. This suggests that acetate
by itself is unable to increase BV2 cell fatty acid content. Studies have demonstrated
conflicting results regarding the effects of LPS on β-oxidation of lipids in different
tissues (Feingold et al. 2009, Feingold et al. 2008, Memon et al. 1998). However, it is
plausible that acetate treatment may reduce the β-oxidation of fatty acids rather than
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stimulating de novo synthesis. Further studies are required to determine the impact
acetate treatment has on the β-oxidation and the de novo synthesis of fatty acids
Fatty acids get incorporated into phospholipid pools and together with cholesterol
control biological membrane order or fluidity (van Meer et al. 2008). Thus, to determine
if increased fatty acid content further alters the phospholipid content, we quantified levels
of individual phospholipid classes. Lack of changes in the phospholipid content at 2 h
suggests that longer treatment periods or higher sample sizes may be required to detect
appreciable changes in the total phospholipid content, although changes in the fatty acid
composition of the individual phospholipid classes cannot be ruled out. Alternatively, it
is possible that the increase in fatty acids observed with acetate may be used for
triglyceride and cholesteryl ester formation. In this regard, LPS stimulation in murine N9
microglia results in the formation of lipid droplets that are highly rich in triglycerides and
cholesteryl esters (Khatchadourian et al. 2012). Therefore, it will be interesting to study
the effects of acetate on the fatty acid content of neutral lipids in different cellular
compartments. Because phospholipase A2 activation and eicosanoid synthesis occur
utilizing specialized cellular phospholipid pools (Murakami et al. 2000) understanding
the impact that acetate treatment has on fatty acid deposition and eicosanoid signaling is
an exciting subject for future investigation.
Radio-labeled acetate is incorporated into cholesterol (Hellman et al. 1954)
however whether high concentrations of acetate can stimulate cholesterol synthesis is not
known. In this regard, our results demonstrate that 5 mM acetate significantly increases
(11%) total cholesterol levels in BV2 microglia. Absence of changes in cholesterol levels
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with 10 mM acetate may partially be explained by the reversible lysine acetylation of the
cytoplasmic 3-hydroxy- 3-methylglutaryl CoA synthase 1(HMGCS1), an enzyme
catalyzing the first and critical step in cholesterol synthesis (Goldstein & Brown 1990).
Protein lysine acetylation is emerging as a ubiquitous mechanism for regulating cellular
metabolism (Zhao et al. 2010) and it has been demonstrated that deacetylation of the
mitochondrial HMGCS2 by sirtuin 3 reduces its activity (Shimazu et al. 2010).
Likewise, it has been demonstrated that the cytoplasmic HMGCS1 gets reversibly
acetylated and is a substrate for cytoplasmic sirtuin 1-dependent deacetylation (Hirschey
et al. 2011). Thus, we speculate that higher concentrations of acetate may induce the
acetylation of HMGCS1 resulting in its deactivation and prevent stimulation of
cholesterol synthesis. Since cholesterol is important in maintaining cellular membrane
rigidity (Giusto et al. 2002) a proportionate increase, relative to the phospholipid content
is essential. Thus, future studies will test the effect of acetate on the cholesterol-tophospholipid ratio and the fatty acid composition of phospholipids with longer treatment
durations.
In addition to increasing fatty acid and cholesterol content, acetate
supplementation has anti-inflammatory properties (Brissette et al. 2012, Reisenauer et al.
2011) that can further augment its therapeutic efficacy in the treatment of
neurodegenerative disorders that have a strong inflammatory component. The underlying
mechanism for the anti-inflammatory effects of acetate is thought to be mediated by an
increase in histone acetylation and involves a disruption of the mitogen-activated protein
kinases, Nf-κB, and eicosanoid signaling (Soliman et al. 2013a, Soliman et al. 2013b,
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Soliman et al. 2012a, Soliman & Rosenberger 2011, Soliman et al. 2012b). In this
context, we demonstrated that in BV2 microglia acetylated H3K9 is associated with the
promoter regions of cyclooxygenase 1 and 2, interleukin-1β and p65 genes that are
involved in inflammation (Soliman et al. 2013b). Therefore, we selected BV2 cells to
study the effect of different acetate concentrations on the acetylation-state of nuclear
histones. We expanded the scope of this study to include H4S1/K5/K8/K12 acetylation
in addition to H3K9 and examined the time required by 10 mM acetate to alter the
acetylation-state of these histones. These results suggest that acetate-induced increase in
H3K9 acetylation requires 4 h to show a significant change however H4 acetylation starts
as soon as 0.5 h following acetate treatment. Interestingly, H4 acetylation increased in a
time-dependent manner suggesting a progressive increase in multiple lysine and/or serine
residues that get acetylated with time. Further, the concentration-response effect of
acetate on the acetylation-state of H3 and H4 showed that the minimum concentration of
acetate required to stimulate histone acetylation was 5 mM for both H3 and H4.
Collectively, these results and the effect of acetate on lipid content suggest that acetateinduced increase in fatty acid content may precede histone acetylation. This conclusion
is supported by studies demonstrating that attenuated expression of ACC, the ratelimiting enzyme in de novo fatty acid synthesis, increases global histone acetylation and
alters transcriptional regulation (Galdieri & Vancura 2012).
In conclusion, acetate supplementation stimulates purine metabolism in whole
brain and glial cultures which may contribute to the anti-inflammatory effects of glyceryl
triacetate. However, future studies are required to more conclusively establish the role of
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acetate-induced purine metabolism in altering neuroinflammation for designing targeted
drug therapies for the treatment of neurodegenerative disorders. Furthermore, although
preliminary, acetate increases fatty acid content and cholesterol levels in BV2 microglia.
Future studies will test the effect of acetate supplementation in demyelinating rodent
models such as the experimental-autoimmune encephalomyelitis and will be instrumental
in developing therapeutic strategies for the treatment of diseases like multiple sclerosis
and Canavan disease. Finally, differential effects of distinct acetate concentrations on
lipid synthesis and histone acetylation may provide the foundation for the development of
novel therapeutic strategies in the treatment of disorders requiring either enhanced lipid
synthesis, or attenuation of inflammation.

Summary and Significance
Neuroinflammation can lead to neuronal dysfunction and degeneration as found in
many neurological diseases such as Alzheimer, Parkinson, Huntington, Amyotrophic
lateral sclerosis, and Multiple sclerosis. Although impaired brain energy metabolism and
neuroinflammation are important contributing factors of neurodegeneration, therapeutic
strategies targeting energy impairment to reduce injury have not been exploited. Our lab
has demonstrated that acetate supplementation is anti-inflammatory and neuroprotective
in rat models of neuroinflammation (Reisenauer et al. 2011) and Lyme neuroborreliosis
(Brissette et al. 2012). Other studies have demonstrated its potential as a metabolic
support during brain injury (Arun et al. 2010a), it improves the tremor phenotype in a
Canavan disease model (Arun et al. 2010b), and has also been shown to possess growth
arresting properties in gliomas (Tsen et al. 2013). However, the exact mechanism(s)
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involved in the beneficial effects of acetate supplementation are not well understood.
The focus of this work was to better understand the mechanisms by which an increase in
brain acetyl-CoA levels through purine and lipid metabolism can attenuate inflammation
and offer neuroprotection.
Acetate supplementation in rats increases plasma acetate and brain acetyl-CoA
levels (Reisenauer et al. 2011) and this increase in acetyl-CoA levels is thought to be the
fundamental step in propagating the biological effects of acetate. Since acetyl-CoA is a
ubiquitous substrate for several biochemical pathways such as carbohydrate, protein, and
lipid metabolism, there can be multiple mechanisms (Figure 21) underlying the
protective effects of acetate supplementation. Thus, gaining a better understanding of
acetate’s role in altering acetyl-CoA-dependent metabolic pathways can provide
mechanistic insights into the protective effects of acetate supplementation. Earlier our
lab characterized the effects of acetate supplementation in altering brain and glial culture
histone and non-histone protein acetylation, and inflammatory signaling (Soliman et al.
2013a, Soliman et al. 2013b, Soliman et al. 2012a, Soliman & Rosenberger 2011,
Soliman et al. 2012b). Alternatively, radio-labeled acetate gets incorporated in the TCA
cycle, and the fatty acid and cholesterol synthesis pathways (Hellman et al. 1954,
Howard et al. 1974, Wyss et al. 2011), however the effect that increasing acetate
availability has on energy or purine and lipid levels has not been studied. Moreover, the
link between acetate’s potential to increase brain energy or purine and/or lipid
metabolisms and its anti-inflammatory and neuroprotective effects has not been
investigated.
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Figure 21: Acetate supplementation stimulates acetyl-CoA pathways.
Acetate supplementation increases brain acetyl-CoA levels which stimulate three primary pathways: TCA cycle, protein acetylation,
and lipid synthesis. We have shown that acetyl-CoA through the TCA cycle increases brain PCr and reduces AMP levels. Purines
and their breakdown product, adenosine are potent modulators of inflammation. In this regard, acetate alters the levels and activity of
enzymes, and receptors involved in purine metabolism and signaling. Since acetate increases acetylation of histone and non-histone
proteins which alter gene expression we postulate that changes in histone acetylation are responsible for the altered purinergic enzyme
and receptor levels observed with acetate supplementation. We further believe that this altered purinergic machinery results in altered
purinergic signaling whereby the neuroinflammatory balance is shifted towards anti-inflammation. Furthermore, acetate increases the
fatty acid and cholesterol content in BV2 microglia which suggests that acetate has the potential to increase lipid deposition in
demyelinating or insufficient myelin synthesis disorders such as multiple sclerosis and Canavan disease.

This study investigates key aspects of the two major acetyl-CoA pathways: the
tricarboxylic acid (TCA) cycle, and lipid synthesis. The TCA cycle is responsible for
energy generation and linked to purine metabolism. Purines and their degradation
product, adenosine are important signaling molecules that mediate inflammation. On the
other hand, lipids are important components of biological membranes and also play
important roles in energy storage, signal transduction, and post-translational protein
modifications. Thus, we proposed that acetate supplementation by increasing acetyl-CoA
levels stimulates purine and lipid metabolism which in turn reduce inflammation and
increase lipid deposition.
To begin to test this hypothesis, we measured the effect that short-term acetate
supplementation has on brain purine levels and demonstrated that acetate not only
increases brain energy reserves but can potentially alter brain purine metabolism (Bhatt et
al. 2013). Using long-term acetate supplementation this study also highlighted
differences between acetate supplementation and its close metabolic correlate, the
ketogenic diet. Results of this study further raised the possibility that neurons could also
utilize acetate at least at higher concentrations challenging the accepted convention of
preferential astrocytic or glial acetate utilization. Furthermore, using different acetate
supplementation regimens we tested the potential of acetate in altering purinergic
enzymes and receptors. In these studies, we demonstrated that both prophylactic and
interventional acetate supplementation modulate LPS-induced alterations in the levels
and activity of enzymes involved in adenosine metabolism, and adenosine receptor levels
(Smith et al. 2013). These findings are important because they suggest that acetate
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supplementation can be used to enhance the effects of an endogenous anti-inflammatory
molecule, adenosine. To further determine the mechanism(s) by which acetate
supplementation alters purine metabolism and inflammation we used in vitro cell cultures
of BV2 microglia and primary astrocytes, the cells types involved in initiating and/or
mediating the inflammatory response. Although we found that the in vitro acetate
treatment reversed LPS-induced expression of enzymes and receptors involved in
adenosine metabolism, these data did not completely correspond to our in vivo results.
Findings from these experiments supported the hypothesis that acetate can alter
purinergic metabolism and underscored the importance of paracrine signaling between
different brain cell types for the study of purinergic signaling.
Further, we developed a highly sensitive high performance liquid
chromatography-based method capable of detecting and accurately quantifying low levels
of adenine nucleotides and adenosine in cell cultures (Bhatt et al. 2012). Using this
method we found that acetate initially increased astrocytic energy levels, followed by
reduction in intracellular adenine nucleotides while maintaining a normal energy charge
ratio. These data strengthen the premise that acetate alters energy and purine metabolism
and further suggest that in astrocytes acetate can increase adenine nucleotide release
which are substrates for extracellular purinergic enzymes and agonists for purinergic
receptors. However, using the same method we were unable to find appreciable changes
in the extracellular levels of adenosine in primary astrocytes as well as BV2 microglia.
These studies suggest that either acetate does not affect extracellular adenosine levels or
if it does increase them then elaborate in vitro models need to be designed that are
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amicable to greater control over adenosine metabolism with intact intercellular
communication. Regardless of whether acetate can directly increase in vitro adenosine
levels or not, our in vivo results suggest that acetate can modulate LPS-induced changes
in the purinergic setup that is more suited to alter the response to release of endogenous
adenosine and adenine nucleotides. These studies further accentuate the importance of
studying the purinergic P2X and P2Y receptor mediated pro-inflammatory component of
purinergic signaling. Lastly, our study of the effects of acetate on fatty acid,
phospholipid, and cholesterol content showed that acetate-induced acetyl-CoA can
increase fatty acid and cholesterol content in BV2 cells (Bhatt & Rosenberger 2013).
This proof-of-principle experiment suggested that acetate supplementation may be
utilized for stimulating lipid synthesis. Further, these experiments also provide
background information required for the development of novel therapeutic strategies that
can selectively target disorders requiring either enhanced lipid synthesis, or attenuation of
inflammation.
Collectively these studies demonstrate that acetate supplementation increases
purine metabolism and lipid content in brain and glial cultures and supports the
hypothesis that these in turn may contribute to the anti-inflammatory effects and lipid
deposition potential of acetate. This dissertation work is significant because it provides
fundamental knowledge required for the development of acetate supplementation as an
alternative therapeutic strategy in the treatment of neuroinflammation and
neurodegenerative disorders.
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APPENDICES

Abbreviations
A2AR

Adenosine A2A receptor

ACC

Acetyl-CoA carboxylase

aCSF

Artificial cerebral spinal fluid

ADA

Adenosine deaminase

ADO

Adenosine

ADP

Adenosine diphosphate

AK

Adenosine kinase

AMP

Adenosine monophosphate

AMPCP

α, β-methylene adenosine diphosphate

ANOVA

Analysis of variance

APP α

Amyloid-β precursor protein

ARA

Archidonate

ATP

Adenosine triphosphate

BSA

Bovine serum albumin

CD 14

Cluster of differentiation 14, a pattern recognition receptor.

CD 39

Ecto-apyrase

CD73

Ecto-5’-nucleotidase

CerPCho

Sphingomyelin

ChoGpl

Choline glycerophospholipids
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CMF-HBSS

Ca2+/Mg2+free Hanks balanced salt solution

Cn

Creatinine

CNS

Central nervous system

Cr

Creatine

DGLA

Dihomo-γ-linoleate

DHA

Docosahexaenoate

DMEM/F12

Dulbe’co's Modified Eagle Medium/Nutrient Mixture F-12

DMSO

Dimethyl sulfoxide

ECR

Energy charge ratio

EDTA

Ethylenediaminetetraacetic acid

EGTA

Ethyleneglycoltetraacetic acid

EPA

Eicosapentaenoate

EtnGpl

Ethanolamine glycerophospholipids

FAME

Fatty acid methyl esters

FAS

Fatty acid synthase

FBS

Fetal bovine serum

Freon

Trichlorotrifluromethane

GFAP

Immuno-fluorescence staining

GTA

Glyceryl triacetate

GTP

Guanosine triphosphate

H3

Histone 3

H3K9

Histone 3 acetylated at lysine 9
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H4

Histone 4

H4S1/K5/K8/K12

Histone 4 acetylated at serine 1, and lysine 5, 8, or 12

HEPES

2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, buffer

HIP

n-hexane:2-propanol (3:2, by Vol)

HPLC

High performance liquid chromatography

IL-1β

Interleukin-1β

KH2PO4

Potassium phosphate

LDH

Lactate dehydrogenase

LNA

Linoleate

LPS

Lipopolysaccharide

NaAc

Sodium acetate

NaCl

Sodium chloride

NAD

Nicotinamide adenine dinucleotide

NMDA

N-Methyl-D-aspartic acid

OLA

Oleate

PAM

Palmitate

PBS

Phosphate buffer saline

PCr

Phosphocreatine

PMSF

Phenylmethanesulfonylfluoride

PtdIns

Phosphatidylinositol

PtdSer

Phosphatidylserine

PVDF

Polyvinylidene fluoride
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ROS

Reactive oxygen species

SD

Standard Deviation

SDS

Sodium dodecyl sulfate

STA

Stearate

TBAP

Tetrabutylammonium phosphate

TBS-T

Tris buffered saline containing Tween 20

TCA cycle

Tricarboxylic acid cycle

TEMED

N,N,N’,N’-tetramethylene-diamine

TLC

Thin layer chromatography

TLR 4

Toll-like receptor 4

TNS

6-(p-Toluidino)-2-napthalenesulfonic acid sodium salt

UV

Ultraviolet
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